1041. Friedman, A. P., Treatment of vascular headache, International Encyclopedia of Pharmacology and Therapeutics, Section 33, Vol. 1: 225-231. Carpi, A., Ed., Pergamon Press, New York, 1972.

1042. Fromm, G. H., Pharmacological consideration of anticonvulsants, Epilepsy Abstracts, 2: 194, 1969.

1043. Frost, J. B., Mesoridazine and chlorpromazine in the treatment of alcohol withdrawal syndrome, Canad. Psychiat. Assoc. J. 18: 385-387, 1973.

1044. Gabler, W. L. and Hubbard, G. L., The metabolism of 5,5-diphenylhydantoin (DPH) in nonpregnant and pregnant Rhesus monkeys, Arch. Int. Pharmacodyn., 203: 72-91, 1973.

1045. Gabreels, F. J. M., The influence of phenythoin on the Purkinje cell of the rat, Epilepsy Abstracts, 4:131-132, 197 1.

1046. Gallagher, B. B., Baumel, I. P., Mattison, R. H., and Woodbury, S. G., Primidone, diphenylhyclantoin and phenobarbital: aspects of acute and chronic toxicity, Neurology, 23: 145-149, 1973.

1047. Gamstorp, I., Meeuwisse, G., and Tryding, N., Tryptophan loading test in convulsive disorders, Acta Paediat. Scand., 55: 656-657, 1966.

1048. Gardner-Medwin, D., Why should we measure serum levels of anticonvulsant drugs in epilepsy? Clinical Electroencephalography, 4: 132-134, 1973.

1049. Gardner, C. R. and Webster, R. A., The effect of some anticonvulsant drugs on leptazol and bicuculline induced acetylcholine efflux from rat cerebral cortex, Brit. J. Pharmacol., 47: 652P,1973.

1050. Garrettson, L. K. and Curley, A., Dieldrin-studies in a poisoned child, Arch. Environ. Health, 19: 814-822, 1969.

1051. Garrettson, L. K., Pharmacology of anticonvulsants, Pediat. Clin. N. Amer., 19: 179-191, 1972.

1052. Gattenlohner, W. and Schneider, K. W., The effect of diphenylhydantoin on hemodynamics, Munchen Med.. Wschr.,

11: 2561-2566, 1969.

1053. Gauchel, F. D., Lehr, H. J., Gauchel, G., and von Harnack, G. A., Diphenylhydantoin in children, Deutsch Med. Wscht., 98: 1391-1396, 1973.

1054. Gauchel, G., Gauchel, F. D., and Birkofer, L., A micromethod for the determination of phenytoin in blood by high speed liquid chromatography, Epilepsy Abstracts, 6: 210, 1973.

1055. Gavrdescu, S., Pop, T., and Goia, E., On a case of supraventricular paroxysmal tachycardia resistant to treatment. Transitory conversion into atrial fibrillation by rapid atrial electric stimulation, Med. Intern (Bucur), 24: 1393-1400, 1972.

1056. Gebauer, D., Prevention and therapy of cardiac rhythm disorders. Experiences with a diphenylhydantoin-meprobamate preparation (Cusitan), Munchen Med. Wschr., 11 3: 436-440, 1971.

1057. Gegick, C. G., Danowski, T. S., Khurana, R. C., Vidalon, C., Nolan, S., Stephan, T., Chae, S., and Wingard, L., Hyperostosis frontalis interna and hyperphosphatasemia, Ann. Intern. Med., 79: 71-75, 1973.

1058. Gebres, L. D., Randall, C. L., Riccio, D. C., and Vardaris, R. M., Attenuation of hypothermic retrograde amnesia produced by pharmacologic blockage of brain seizures, Physiol. Behav., 10: 1011-1017, 1973.

1059. Gerber, N., Lynn, R., and Oates, J., Acute intoxication with 5,5-diphenylhydantoin associated with impairment of biotransformation, Ann. Intern. Med., 77: 765-771, 1972.

1060. Gerber, N., Seibert, R. A., and Thompson, R. M., Identification of a catechol glucuronide metabolite of 5,5-diphenylhydantoin (DPH) in rat bile by gas chromatography (GC) and mass spectrometry (MS), Epilepsy Abstracts, 7: 80, 1974.

1061. Gerber, N., Weller, W. L., Lynn, R., Rangno, R. E., Sweetman, B. J., and Bush, M. T., Study of dose-dependent metabolism of 5,5-diphenylhydantoin in the rat using new methodology for isolation and quantitation of metabolites in vivo and in vitro, J. Pharmacol. Exp. Ther., 178: 567-579, 197 1.

1062. Gerich, J. E., Charles, M. A., Levin, S. R., Forsham, P. H., and Grodsky, G. M., In vitro inhibition of pancreatic glucagon secretion by diphenylhydantoin, J. Clin. Endocr., 35: 823-824,1972.

1063. Gerlings, E. D., and Gilmore, J. P., Some cardiac effects of diphenylhydantoin, Acta Physiol Pharmacol Neerl., 15: 461-468, 1969.

1064. German, J., Kowal, A., and Ehlers, K. H., Trimethadione and human teratogenesis, Teratology, 3: 349-362, 1970.

1065. Gerson, C. D., Hepner, G. W., Brown, N., Cohen, N., Herbert, V., and Janowitz, H. D., Inhibition by diphenylhydantoin of folic absorption in man, Gastroenterology, 63: 246-251, 1972.

1066. Getz, H. O., Dilantin against “painful touching” (dysthesia), Physician’s Drug Manual, 3: 144, 1972.

1067. Gettes, L. S., The electrophysiologic effects of antiarrhythmic drugs, Amer. J. Cardiol., 28: 526-535, 197 1.

1068. Gharib, H. and Munoz, 1. M., Endocrine manifestations of diphenylhydantoin therapy, Metabolism, 23: 515-524, 1974.

1069. Gianelly, R. E. and Harrison, D. C., Drugs used in the treatment of cardiac arrhythmias, Disease-A-Month, 25-32, January 1969.

1070. Gibson, K. and Harris, P., Diphenylhydantoin and human myocardial microsomal (Na+,K+)-ATPase, Biochem. Biophys. Res. Commun., 35: 75-78, 1969.

1071. Gilbert, J. C., Gray, P., and Heaton, G. M., Anticonvulsant drugs and brain glucose, Biochem. Pharmacol., 20: 240-243, 1971.

1072. Gillis, R. A. and Raines, A., A comparison of the cardiovascular effects of diphenylthiohydantoin and diphenylhydantoin, Europ. J. Pharmacol., 23: 13-18, 1973.

1073. Gimenez-Roldan, S. and Esteban, A., Orbicularis oculi  “myotonia” in hypothyroid myopathy, Europ. Neurol., 9: 44-55, 1973.

1074. Ginwalia, T. M. S., Gomes, B. C., and Nayak, R. P., Management of gingival hyperplasia in patients receiving Dilantin therapy, J. Indian Dent. Assn., 39: 124-126, 1967.

1075. Glaser, G. H., Diphenylhydantoin, toxicity, Antiepileptic Drugs, 219-226, Woodbury, D. M., Penry, J. K., and Schmidt, R. P. Eds., Raven Press, New York, 1972. (cf. Adeloye, et al., Ghana Med. J., 10: 56, 1971, Bosso and Chudzik, Drug Intel. & Clin. Pharma., 7: 336, 1973, Greenberg, et al., Epilepsy Abstracts, 4: 151, 1971 and Watts, Pediatrics, 30: 592, 1962.)

1076. Glazko, A. J. and Chang, T., Diphenylhydantoin, absorption, distribution and excretion, Antiepileptic Drugs, 127-136, Woodbury, D. M., Penry, J. K., and Schmidt, R. P., Eds., Raven Press, New York, 1972.

1077. Glazko, A. J., Diphenylhydantoin, chemistry and methods for determination, Antiepileptic Drugs, 103-112, Woodbury, D. M., Penry, J. K., and Schmidt, R. P., Eds., Raven Press, New York,1972.

1078. Glazko, A. J., Diphenylhydantoin, Epilepsy Abstracts, 6: 184, 1973.

1079. Godfraind, T., Lesne, M., and Pousti, A., The action of diphenylhydantoin upon drug binding, ionic effects and ino- tropic action of ouabain, Arch. Int. Pharmacodyn., 191: 66-73, 1971.

1080. Goebel, R. W., Sodium diphenylhydantoin association with oral healing, J. Oral Surg., 30: 191-195, 1972.

1081. Goldberg, M. A., and Todoroff, T., Binding of diphenylhydantoin to brain protein, Epilepsy Abstracts, 7: 112, 1974.

1082. Goldberg, M. A. and Todoroff, T., Diphenylhydantain binding to brain fractions, Neurology, 22: 410, 1972.

1083. Goldberg, M. E. and Ciofalo, V. B., Effect of diphenylhydantoin sodium and chlordiazepoxide alone and in combination on punishment behavior, Psychopharmacologia (Berlin), 14: 233-239, 1969.

1084. Goldstein, F. J., Continuing education via pharmatapes: Digitalis 1. A basic pharmacological review, Amer. J. Pharm., 145: 135-141, 1973.

1085. Goldstein, R. E., Penzotti, S. C., Kuehl, K. S., Prindle, K. H., Hall, C. A., Titus, E. O., and Epstein, S. E., Correlation of antiarrhythmic effects of diphenylhydantoin with digoxin induced changes in myocardial contractility, sodium-potassium adenosine triphosphatase activity, and potassium efflux, Circ. Res., 33: 175-182,1973.

1086. Gordon, E., Respiratory control after acute head injury, Lancet, 483, 1973.

1087. Gordon, P., Aging: a search for drug-modifiable degeneracy in the polyribosomes of brain, Proc. 8th Int. Cong. Geront., 1: 4pp., 1969,

1088. Gordon, P., Callaghan, O., and Doty, B., Diphenylhydantoin effects on nucleic acid biochemistry learning and neoplasm, Pharmacologist, 10: 169, 1968.

1089. Gordon, P., Molecular approaches to the drug enhancement of deteriorated functioning in the aged, Advances Geront. Res., 3: 199-248, 197 1.

1090. Gordon, P., Rational chemotherapy for aging, Postgrad. Med., 40: 152-155, 1970.

1091. Gordon, P., Tobin, S. S., Doty, B., and Nash, M., Drug effects on behavior in aged animals and man: diphenylhydantoin and procainamide J. Geront., 23: 434-444, 1968.

1092. Gossel, T. A. and Mennear, J. H., Inhibition of alloxan-induced diabetes by diphenylhyantoin sodium, Pharmacologist, 13: 238, 1971.

1093. Gossel, T. A., On the mechanism of diphenylhydantoin protection against alloxan-induced diabetes mellitus in mice, Dissertation Abstracts, 33: 2729B, 1972.

1094. Gottschalk, L. A., Covi, L., Uliana, R., and Bates, D. E., Effects of diphenylhydantoin on anxiety and hostility in institutionalized prisoners, Compr. Psychiat., 14: 503-511, 1973.

1095. Goudie, J. H. and Burnett, D., A gas chromatographic method for the simultaneous determination of phenobarbitone, primidone and phenytoin in serum using a nitrogen detector, Epilepsy Abstracts, 6: 187, 1973.

1096. Grant, R. H. E. and Stores, 0. P. R., Folic acid in folate deficient patients with epilepsy, Brit. Med. J., 4: 644-648, 1970.

1097. Green, R. S. and Rau, J. H., Treatment of compulsive eating disturbances with anticonvulsant medication, Amer. J. Psychiat., 131: 428-432, 1974.

1098. Greenbaum, D. S., Ferguson, R. K., Kater, L. A., Kuiper, D. H., and Rosen, L. W., A controlled therapeutic study of the irritable-bowel syndrome, New Eng. J. Med., 288: 13-16, 1973.

1099. Greenberg, C. and Papper, E. M., The indications for gasserian ganglion block for trigeminal neuralgia, Anesthesiology, 31: 566-573, 1969.

1100. Greenberg, 1. M., Cerebral dysfunction in general psychiatric office practice, Dis. Nerv. Syst., 33: 637-644, 1972.

1101. Greengard, O. and McIlwain, H., Anticonvulsants and the metabolism of separated mammalian cerebral tissues, Biochem. J., 61: 61-68,1955.

1102. Grob, P. J. and Herold, G. E., Immunological abnormalities and hydantoins, Brit. Med. J., 2: 561-563, 1972.

1103. Gruener, R. P. and Stern, L. Z., Diphenylhydantoin reverses membrane effects in steroid myopathy, Nature New Bio., 235: 54-55, 1972.

1104. Gudmundson, C. and Lidgren, L., Does diphenylbydantoin accelerate healing of fractures in mice, Acta Orthop. Scand., 44: 640-649, 1973.

1105. Guzek, J. W., Russell, J. T., and Thorn, N. A., Inhibition by diphenylhydantoin of vasopressin release from isolated rat neurohypophyses, Atia Pharmacol. et Toxicol., 34: 1-4, 1974.

1106. Haan, D., Diagnosis and therapy of cardiac arrhythmia and acute heart disease, Medizinisch Literarische Verlagsgesellschaft mbH, Uelzen, Germany, 1973.

1107. Haddad, R. I., Positive EEG spike activity in sleep, JAMA, 229: 1282, 1974.

1108. Hadfield, M. G. and Boykin, M. E., Effect of diphenylhydantoin administered in vivo on 3H-1-norepinephrine uptake in synaptosomes, Res. Commun. Chem. Pathol. Pharmacol., 7: 209-212, 1974.

1109. Hadfield, M. G., Uptake and binding of catecholamines -effect of diphenylhydantoin and a new mechanism of action, Arch. Neurol., 26: 78-84, 1972.

1110. Haft, J. I., Ricciutti, M. A. and Damato, A. N., Effects of IV diphenylhydantoin (DPH) on coronary blood flow and oxygen utilization of the heart, Clinical Research, 15: 204, 1967.

1111. Hagen, H., Treatment of cardiac arrhythmias with diphenylhydantoin, Deutsch Med. Wschr., 96: 380-384, 197 1.

1112. Haghshenass, M. and Rao, D. B., Serum folate levels during anticonvulsant therapy with diphenylhydantoin, J. Am. Geriat. Soc., 21: 275-277, 1973.

1113. Hahn, T. J., Hendin, B. A., Scharp, C. R., and Haddad, G., Jr., Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults, New Eng. J. Med., 287: 900-909, 1972.

1114. Haiat, R., Chapelle, M., Benaim, R., Witchitz, S., and Chiche, P., Disappearance of an intraventricular conduction disorder under diphenylhydantoin, Sem. Hop. Paris, 47: 2957-2964, 1971.

1115. Hall, W. B., Prevention of Dilantin hyperplasia: a preliminary report, Bull. Acad. Gen. Dent., 20-25, 1969.

1116. Hallaq, I. Y. and Harris, J. D., The syndrome of postherpetic neuralgia: complication and an approach to therapy, J. Amer. Osteopath. Assoc., 68: 1265-1267, 1969.

1117. Halpern, L. M. and Julien, R. M., Augmentation of cerebellar Purkinje cell discharge rate after diphenylhydantoin, Epilepsy Abstracts, 5: 236-237, 1972.

1118. Hancock, J. C. and Bevilacqua, A. R., Temporal lobe dysrhythmia and impulsive or suicidal behavior, Southern Med. J. 64: 1189-1193, 1971.

1119. Handley, A. J., Phenytoin tolerance tests, Brit. Med. J. 3: 203-204, 1970.

1120. Hansen, H. W. and Wagener, H. H., Sodium diphenylhydantein for the treatment of cardiac arrhythmias, Munchen Med. Wschr., 111: 417-421, 1969.

1121. Hansen, H. W. and Wagener, H. H., Diphenylhydantoin in the treatment of heart failure, Deutsch. Med. Wschr., 96: 1866-1873, 1971.

1122. Hansen, H. W. and Wagener, H. H., Experimental studies an the influence of diphenylhydantoin glycoside effects on the heart, Herz Kreislauf Zeitschrift Fur Kardiologie und Angiologie in Klinik und Praxis, 6: 69-72, 1974.

1123. Hansen, H. W., Marquort, B., and Pelz, W., Indications for phenytoin in cardiac arrhythmias, Deutsch. Med. Wschr., 99: 638-642, 1974.

1124. Hansen, J. M., Siersbaek-Nielsen, K. and Skovsted, L., Effect of diphenyihydantoin on the metabolism of carbamazepine-induced acceleration of dicoumarot in man, Acta Med. Scand., 189: 15-19, 197 1.

1125. Hansen, J. M., Skovsted, L., Lauridsen, U. B., Kirkegaard, C., and Siersbaek-Nielsen, K., The effect of diphenylhydantoin on thyroid function, J. Clin. Endocrinol. Metab., 39: 785-786, 1974.

1126. Hansotia, P. and Keran, E., Ditantin binding by red blood cells of normal subjects, Neurology, 24: 575-578, 1974.

1127. Hansten, P. D., Diphenylhydantoin drug interactions, Hosp. Formulary Manage., 4: 28-29, 1969.

1128. Haque, N., Thrasher, K., Werk, E. E., Jr., Knowles, H. C., J r., and Sholiton, L. J., Studies on dexamethasone metabolism in man: effect of diphenylhydantoin, J. Clin. Endocr., 34: 44-50, 1972.

1129. Harbison, R. D. and Becker, B. A., Effect of phenobarbital and SKF 525A pretreatment on diphenylhydantoin teratogenicity in mice, J. Pharmacol. Exp. Ther., 175: 283-288, 1970.

1130. Harbison, R. D., Eling, T. E., and Becker, B. A., Effects of diphenylhydantoin on neonatal rat liver drug metabolizing enzymes, Fed. Proc., 28(2): 1969.

1131. Harris, M., Jenkins, M. V. and Wills, M. R. Phenytoin inhibition of parathyroid hormone induced bone resorption in vitro. Brit. J. Pharmac., 50: 405-408, 1974.

1132. Harrison, D. C., Kerber, R. E., and Alderman, E. L., Pharmacodynamics and clinical use of cardiovascular drugs after cardiac surgery, Amer. J. Cardiol., 26: 385-393, 1970.

1133. Hart, B. L., Feline behavior, Feline Practice, 3: 8-10, 1973.

1134. Hartshorn, E. A., Interactions of cardiac drugs, Drug Intell. Clin. Pharm., 4: 272-275, 1970.

1135. Hartshorn, E. A., Pyrazolone derivatives (antipytine, aminopyrine, phenylbutazone, oxyphenbutazone), Drug Intelligence Clinical Pharmacy, 6: 6-10, 1972.

1136. Hasbani, M., Pincus, J. H. and Lee, S. H., Diphenylhydantoin and calcium movement in lobster nerves, Arch. Neurol., 31: 250-254, 1974.

1137. Hatch, R. C. and Fischer, R., Cocaine elicited behavior and toxicity in dogs pretreated with synaptic blocking agents, morphine, or diphenylhydantoin, Epilepsy Abstracts, 6: 209, 1973.

1138. Hattwick, M. A. W., Weis, T. T., Stechschulte, C. J., Baer, G. M., and Gregg, M. B., Recovery from rabies: a case report, Ann. Intern. Med., 76: 931-942, 1972.

1139. Haward, L. R. C., Effects of sodium diphenylhydantoinate and pemoline upon concentration: a comparative study, Drugs and Cerebral Function, 103-120, Smith, W. L., Ed., Charles C Thomas, 1970.

1140. Haward, L. R. C., Effects of DPH (sodium diphenylhydantoinate) upon concentration in pilots, Rev. Med. Aeronautique Spatiale, 12: 372-374, 1973.

1141. Haward, L. R. C., The effect of phenytoin-aided autogenic training on stress threshold, Int. Congress for Psychosomatic Med. and Hypnosis, Kyoto, Japan, July 12-14, 1967.

1142. Haward, L. R. C., Effects ofsodium diphenylhydantoin upon concentration, Bulletin Brit. Psychol. Soc., 22: 50, 1969.

1143. Hedger, R. W., The conservative management of acute oliguric renal failure, Med. Clin. N. Am”., 55: 121-135, 197 1. 1144. Heinemann, U. and Lux, H. D., Effects of diphenylhy dantoin on extracellular (K+) in cat cortex, Electroenceph. Clin. Neurophysiol., 34: 735, 1973.

1145. Helfant, R., Scherlag, B., and Damato, A., The interaction of procaine amide and diphenylhydantoin on cardiac conductivity and automaticity, Clin. Res., 15: 206, 1967.

1146. Hendricks, G. L., Jr., Barnes, W.T., and Hood, H. L., Seven-year “cure” of lung cancer with metastasis to the brain, JAMA, 220: 127,1972.

1147. Hepner, G. W., Aledort, L. M., Gerson, C. D., Cohen, N., Herbert, V., and Janowitz, H. D., Inhibition of intestinal ATPase by diphenylhydantoin and acetazolamide, Clin. Res., 18: 382, 1970.

1148. Herbinger, W., Result report of a control by an apparatus of 208 myocardial infarct patients in an intensive care station, Wien. Med. Wschr., 121: 518-522, 1971.

1149. Hermansen, K., Antifibrillatory effect of some beta-adrenergic receptor blocking agents determined by a new test procedure in mice, Acta Phamacologica, 28: 17-27, 1969.

1150. Hinkhouse, A., Craniocerebral trauma, Am. J. Nurs., 73: 1719-1722, 1973.

1151. Hobson, J. D. and Zettner, A., Digoxin serum half-life following suicidal digoxin poisoning, JAMA, 223: 147-149, 1973.

1152. Hodgson, E. R. and Reese, H. H., Clinical experiences with dilantin in epilepsies, Wis. Med. J., 38: 968-971, 1939.

1153. Hoefer, P. F. A., Cohen, S. M., and Greeley, D. McL., Paroxysmal abdominal pain-a form of epilepsy in children, JAMA, 147: 1-6, 195 1.

1154. Hofeldt, F. D., Dippe, S. E., Levin, S. R., Karam, J. H., Blum, M. R., and Forsham, P. H., Effects of diphenylhydantoin upon glucose-induced insulin secretion in three patients with insulinoma, Diabetes, 23: 192-198, 1974.

1155. Hogg, P. S., Three cases of ‘restless legs’ or ‘Ekbom’s syndrome’ as seen in general practice, Practitioner, 209: 82-83, 1972.

1156. Holcomb, R., Lynn, R., Harvey, B., Sweetman, B. and Gerber, N., Intoxication with 5,5-diphenylhydantoin (Dilantin), J. Pediat., 80: 627-632, 1972.

1157. Holdaway, P. A., Effects of amino-glutethimide and diphenylhydantoin sodium on the rat adrenal cortex, Proc. Indiana Acad. Sci., 77: 427-433,1968.

1158. Hommes, 0. R. and Obbens, E. A., The epileptogenic action of Na-folate in the rat, J. Neurol. Sci., 16: 271-281, 1972.

1159. Honda, Y., Podos, S. M., and Becker, B., The effect of diphenylhydantoin on the efectroretinogram of rabbits. I. Effect of concentration, Invest. Ophthal., 12: 567-572, 1973.

1160, Honda, Y., Podos, S. M., and Becker, B., The effect of diphenylhydantoin on the electroretinogram of rabbits. II. Effects of hypoxia and potassium, Invest. Ophthal., 12: 573-578, 1973.

1161. Hooper, W. D., Sutherland, J. M., Bochner, F. et al., The effect of certain -drugs on the plasma protein binding of phenytoin, Epilepsy Abstracts, 7: 112, 1974.

1162. Hopf, H. C. and Kauer, H., Effect of phenytoin on the excitable cell membrane, Epilepsy Abstracts, 4: 89, 197 1.

1163. Houben, P. F. M., Hommes, 0. R., and Knaven, P. H., Anticonvulsant drugs and folic acid in young mentally retarded epileptic patients, Epilepsia, 12: 235-247, 197 1.

1164. Houck, J. C., Cheng, R. F., and Waters, M. D., Diphenylhydantoin, effects on connective tissue and wound repair, Antiepileptic Drugs, 267-273, Woodbury, D. M., Penry, J. K., and Schmidt, R. P., Eds., Raven Press, New York, 1972.

1165. Houck, J. C., Cheng, R. F., and Waters, M. D., The effect of Dilantin upon fibroblast proliferation, Proc. Soc. Exp. Biol. Med., 139: 969-981, 1972.

1166. Houghton, G. W. and Richens, A., Inhibition of phenytoin metabolism by sulthiame in epileptic patients, Brit. J. Clin. Pharmacol., 1: 59-66, 1974.

1167. Houghton, G. W. and Richens, A., Rate of elimination of tracer doses of phenytoin at different steady state serum phenytoin concentrations in epileptic patients, Brit. J. Clin. Pharmacol. 1: 155-161, 1974.

1168. Houghton, G. W., Latham, A. N., and Richens, A., Difference in the central actions of phenytoin and phenobarbitone in man, measured by critical flicker fusion threshold, Europ. J. Clin. Pharmacol., 6: 57-60, 1973.

1169. Huessy, H. R., Study of the prevalence and therapy of the choreatiform syndrome or hyperkinesis in rural Vermont, Acta Paedopsychiat., 34: 130-135, 1967.

1170. Huffman, D. H. and Azarnoff, D. L., The use of digitalis, Ration. Drug Ther., 8: 1-7, 1974.

1171. Hughes, R. C. and Matthews, W. B., Pseudo-myotonia and myokymia, J. Neurol. Neurosurg. Psychiat., 32: 11-14, 1969.

1172. Huisman, J. W., Van Heycop Ten Ham, M. W., and Van Zijl, C. H. W., Influence of ethylphenacemide on serum levels of other anti-epileptic drugs, Epilepsia, 11: 207-215, 1970.

1173. Humphries,J.O.,Newmethodsforthepreventionand treatment of ventricular arrhythmias, Maryland Med. J., 17: 75-76, 1968.

1174. Hunninghake, D. B., Drug interactions, Postgrad. Med., 47: 71-75,1970.

1175. Hunter, J., Maxwell, J. D., Stewart, D. A., Parsons, V., and Williams, R., Altered calcium metabolism in epileptic children on anticonvulsants, Brit. Med. J., 202-204, 197 1. (cf. Hahn, et al., Clin. Res., 21: 626, 1973 and Herman and Pippenger, Neurology, 23: 437, 1973.)

1176. Iber, F. L., Prevention of alcohol withdrawal seizures, JAMA, 221: 608,1972.

1177. Ide, C. H. and Webb, R. W., Penetrating transorbital injury with cerebrospinal orbitorrhea, Amer.J. Ophthal., 71: 1037-1039, 1971.

1178. Idestrom, C. M., Schalling, D., Cariguist, U., and Sjoqvist, F., Acute effects of diphenylhydantoin in relation to plasma levels, Psychol. Med., 2: 111-120, 1972.

1179. Imabayashi, K. and Matsumura, S., Four cases of idiopathic renal hematuria with abnormal electroencephalogram, Jap. J. Clin. Urol., 27: 139-144, 1973,

1180. Inaba, T. and Brien, J. F., Determination of the major urinary metabolite of diphenylhydantoin by high-performance liquid chromatography, J. Chromatogr., 80: 161-165, 1973.

1181. Iosub, S., Bingol, N., and Wasserman, E., The pregnant epileptic and her offspring, Pediat. Res., 7: 420, 1973.

1182. Isaacs, H. and Frere, G., Syndrome of continuous muscle fibre activity. Histochemical, nerve terminal and end-plate study of two cases, South African Medical Journal, 48: 1601-7, 1974.

1183. Isaacs, H., Continuous muscle fibre activity in an Indian male with additional evidence of terminal motor fiber abnormality, J. Neurol. Neurosurg. Psychiat., 30: 126-133, 1967.

1184. Janz, D. and Schmidt, D., Comparison of spectrophotometric and gas liquid chromatographic measurements of serum diphenylhydantoin concentrations in epileptic outpatients, Epilepsy Abstracts, 7: 268, 1974.

1185. Janz, D. and Schmidt, D., Anti-epileptic drugs and failure of oral contraceptives, Lancet, 1113, 1974.

1186. Jenkins, D. and Spector, R. G., The actions of folate and phenytoin on the rat heart in vivo and in vitro, Biochem. Pharmacol., 22: 1813-1816, 1973.

1187. Jensen, 0. N. and Olesen, 0. V., Subnormal serum folate due to anticonvulsive therapy, Arch. Neurol., 22: 181-182, 1970.

1188. Jensen, R. A. and Katzung, B. G., Electrophysiological actions of diphenylhydantoin on rabbit atria: dependence on stimulation frequency, potassium and sodium, Circ. Res., 26: 17-27, 1970.

1189. Jonas, A. D., Diphenylhydantoin and the treatment of anxiety, Amer. J. Psychiat., 126: 163, 1969.

1190. Jones, G. L. and Kemp, J. W., Characteristics of the hydrogen bonding interactions of diphenylhydantoin with nucleic acids and their components, Fed. Proc., 31: 570, 1972.

1191. Jovanovic, T., Experiences in the treatment of psychoses occurring concomitantly with epilepsy, Neuropsihiatrija, 20: 173-183, 1972.

1192. Joynt, R. J. and Green, D., Tonic seizures as a rnanifestation of multiple sclerosis, Arch. Neurol., 6: 293-299, 1962.

1193. Jubiz, W. and Rallison, M. L., Diphenylhydantoin treatment of glycogen storage diseases, Arch. Intern. Med., 134: 418-421, 1974.

1194. Jubiz, W., Levinson, R. A., Meikle, A. W., West, C. D., and Tyler, F. H., Absorption and conjugation of metyrapone during diphenylhydantoin therapy: mechanism of the abnormal response to oral metyrapone, Endrocrinology, 86: 328-331, 1970.

1195. Jubiz, W., Meikle, A. W., Levinson, R. A., Mizutani, S., West, C. D., and Tyler, F. H., Effect of diphenylhydantoin on the metabolism of dexamethasone, New Eng. J. Med., 283: 11-14, 1970.

1196. Julien, R. M. and Halpern, L. M., Cerebellar action of diphenylhydantoin on penicillin-induced cerebral cortical epileptic foci, Fed. Proc., 29: Abstract 784, 1970.

1197. Julien, R. M. and Halpern, L. M., Stabilization of excitable membrane by chronic administration of diphenylhydantoin, J. Pharmacol. Exp. Ther., 175: 206-212, 1970.

1198. Julien, R. M. and Halpern, L. M., Diphenylhydantoin: evidence for a central action, Life Sci., 10: 575-582, 1971.

1199. Julien, R. M. and Halpern, L. M., Effects of diphenylhydantoin and other antiepileptic drugs on epileptiform activity and Purkinje cell discharge rates, Epilepsia, 13: 387-400, 1972.

1200. Jung, S. S., Chen, K. M., Brody, J. A., Paroxysmal choreoathetosis: report of Chinese cases, Neurology, 23: 749-55, 1973.

1201. Jus, K., jus, A., Gautier, J., Villeneuve, A., Pires, P., Flineau, R., and Villeneuve, R., Studies on the action of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome, Int. J. Clin. Pharmacol., 9: 138-145, 1974.

1202. Kalman, P., Nanassy, A., and Csapo, G., Diphenylhydantoin treatment of atrial tachycardia with heart block, Z. Kardiologie, 62: 75-79, 1972.

1203. Kanzawa, F., Hoshi, A., and Kuretani, K., Relationship between antitumor activity and chemical structure in psychotropic agents, Gann, 61: 529-534, 1970.

1204. Kaplan, R., Blume, S., Rosenberg, S., Pitrelli, J., and Turner, W. J., Phenytoin, metronidazole and multivitamins in the treatment of alcoholism, Quart. J. Stud. Alcohol., 33: 97-104, 1972.

1205. Kasai, S. and Yoshizumi, T., Effect of diphenylhydantoin sodium on the proliferation of cultured cells in vitro, Bull. Tokyo Dent. Coll., 12: 223-234, 1971.

1206. Kater, R. M. H., Roggin, G., Tobon, F., Zeive, P., and lber, F. L., Increased rate of clearance of drugs from the circulation of alcoholics, Amer. J. Med. Sci., 258: 35-39, 1969.

1207. Kater, R. M. H., Tobon, F., Zeive, P. D., Roggin, G. M., and Iber, F. L., Heavy drinking accelerates drugs’ breakdown in liver, JAMA, 206: 1709,1968.

1208. Kato, R., Chiesara, E., and Vassanelli, P., Increased activity of microsomal strychnine-metabolizing enzyme induced by phenobarbital and other drugs, Biochem. Pharmacol., 11: 913-922, 1962.

1209. Kaufmann, G. and Hauser, K., Experience with diphenylhydantoin (antisacer) in the treatment of cardiac arrhythmias, Schweiz. Med. Wschr., 98: 1223-1226, 1968.

1210. Kaufmann, G. and Weber-Eggenberger, S., Hemodynarnic changes due to diphenylhydantoin in digitalized cardiac patients, Schweiz. Med. Wschr., 100: 2164-2168, 1970.

1211. Kazamatsuri, H., Elevated serum alkaline phosphatase levels in epilepsy during diphenylhydantoin therapy, New Eng. J. Med., 283: 1411-1412, 1970.

1212. Kazamatsuri, H., Elevated serum alkaline phosphatase levels in the epileptic patients with diphenylhydantoin, Folia Psychiat. Neurol. Jap., 24: 181-189, 1970.

1213. Keltner, J. L., Becker, B., Gay, A. J., and Podos, S. M., Effect of’diphenylhydantoin in ischemic optic neuritis, Trans. Amer. Opthal. Soc., 70: 113-130, 1972.

1214. Kemp, G. L., Treatment of ventricular ectopic rhythms with diphenylhydantoin, J. Amer. Geriat. Soc., 20: 265-267, 1972.

1215. Kemp, J. W. and Woodbury, D. M., Subcellular distribution of 4-C14

-diphenylhydantoin in rat brain, J. Pharmacol. Exp. Ther., 177: 342-349, 1971.

1216. Kennedy, C., Anderson, W., and Sokoloff, L., Cerebral blood flow in epileptic children during the interseizure period, Neurology, 8: 100-105, 1958.

1217. Kennedy, C., Grave, G. D.,Jehle, J. W., and Kupferberg, H. J., The effect of diphenylhydantoin on local cerebral blood flow, Neurology, 22: 451-452, 1972.

1218. Kessler, K. M., Individualization of dosage of antiarrhythmic drugs, Medical Clinics of North America, 58: 1019-26, 1974.

1219. Ketel, W. B. and Hughes, J. R., Toxic encephalopathy with seizures secondary to ingestion of composition C-4, Neurology, 22: 871-876,1972.

1220. Kizer, J. S., Vargas-Cordon, M., Brendel, K., and Bressler, R., The in vitro inhibition of insulin secretion by diphenylhydantoin, J. Clin. Invest., 49: 1942-1948, 1970.

1221. Kleinfeld, M. and Stein, E., Effects of diphenylhydantoin on action potentials of canine Purkinje and ventricular fibers, Circulation, 38: 116, 1968.

1222. Knopp, R. H., Sheinin, J. C., and Freinkel, N., Diphenylhydantoin and an insulin-secreting islet adenoma, Arch. Intern. Med., 130: 904-908, 1972.

1223. Kobayashi, I., Yamashita, Y., and Yamazaki, H., Onset of systemic lupus erythematosus during the long-term administration of diphenylhydantoin, Nippon Naika Gakhai Zasshi, 60: 851-854, 1971.

1224. Koch-Weser, J., Antiarrhythmic prophylaxis in arnbulatory patients with coronary heart disease, Arch. Intern. Med., 129: 763-772, 1972.

1225. Koch, A., Higgins, R., Sande, M., Tierney, J., and Tulin, R., Enhancement of renal Na+ transport by Dilantin, Physiologist, 5: 168, 1962.

1226. Koch, H. U., Kraft, D., Von Herrath, D., and Schaefer, K., Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat, Epilepsy Abstracts, 6: 109, 1973.

1227. Kootstra, A. and Woodhouse, S. P., The effect of diphenylhydantoin on the N+-K+-stimulated ouabain-inhibited ATPase, Proceedings of the University of Otago Medical School, 52: 67, 1974.

1228. Koppe, J. G., Bosman, W., Oppers, V. M., Spaans, F., and Kloosterman, G. J., Epilepsy and congenital anomalies, Ned. T. Geneesk., 117: 220-224, 1973. (cf. Loughnan, et al., Lancet, 70, 1973.)

1229. Kormendy, C. G. and Bender, A. D., Experimental modification of the chemistry and biology of the aging process, J. Pharm. Sci., 60: 167-180, 197 1.

1230. Koski, C. L., Rifenberick, D. H., and Max, S. R., Energy metabolism in steroid atrophy, Neurology, 4: 352, 1974.

1231. Kostov, K. G., Tachev, A. M. and Nastev, G. T., The problem of pseudomyotonia (Isaac’s syndrome), Zh. Neuropatol. Psikhiatr. Korsakov, 73: 825-829, 1973.

1232. Krasner, J., Drug-protein interaction, Pediat. Clin. N. Amer., 19: 51-63, 1972.

1233. Krasner J.,Giacoia, G.P.,and Yaffe, S.J., Drug protein binding in the newborn infant, Pediat. Res., 7: 317, 1973.

1234. Krell, R. D. and Goldberg, A. M., Effect of diphenylhydantoin and ethanol feeding on the synthesis of rat liver folates from exogenous pteroylglutamate (3H), Epilepsy Abstracts, 7: 195, 1974.

1235. Krikler, D. M., A fresh look at cardiac arrhythmias, Lancet, 1034-1037, 1974.

1236. Krsiak, M. and Steinberg, H., Psychopharmacological aspects of aggression: a review of the literature and some new experiments, J. Psychosom. Res., 13: 243-252, 1969.

1237. Kruger, G., Effect of Dilantin in mice. 1. Changes in lyinphoreticular tissue after acute exposure, Virshows Arch. (Path. Anat.), 349: 297-311, 1970. (cf. Juhasz, et al., Acta Morphol. Acad. Sci. Hung., 18: 147, 1970.)

1238. Krupin, T., Podos, S. M., and Becker, B., Effect of diphenylhydantoin on dexamethasone suppression of plasma cortisol in primary open-angle glaucoma, Amer. J. Ophthal., 71: 997-1002, 1971.

1239. Kuiper, J. J., Lymphocytic thyroiditis possibly induced by diphenylhydantoin, JAMA, 210: 2370-2372, 1969.

1240. Kuntzman, R. and Southern, A. L., The effects of CNS active drugs on the metabolism of steroids in man, Adv. Biochem. Psychopharmacol., 1: 205-217, 1969.

1241. Kupferberg, H. J., Quantitative estimation of diphenylhydantoin, primidone and phenobarbital in plasma by gasliquid chromatography, Clin. Chim. Atia, 29: 283-288, 1970.

1242. Kuroiwa, Y. and Araki, S., Lhermitte’s sign and reflex tonic spasm in demyelinating diseases with special reference to their localizing value, Kyushu J. Med. Sci., 14: 29-38, 1963.

1243. Kuroiwa, Y. and Shibasakil H., Painful tonic seizures in multiple sclerosis-treatment with diphenylhydantoin and carbamazepine, Folia. Psychiat. Neurol. Jap., 22: 107-119, 1968.

1244. Kutt, H. and Fouts, J. R., Diphenylhydantoin rnetabolism by rat liver microsomes and some of the effects of drug or chemical pretreatment on diphenylhydantoin metabolism by rat liver microsomal preparations, J. Pharmacol. Exp. Ther., 176: 11- 26, 1970.

1245. Kutt, H. and Penry, J. K., Usefulness of blood levels of antiepileptic drugs, Arch. Neurol., 31: 283-288, 1974.

1246. Kutt, H. and Verebely, K., Metabolism of diphenylhydantoin by rat liver microsomes, Biochem. Pharmacol., 19: 675-686, 1970.

1247. Kutt, H., Biochemical and genetic factors regulating Dilantin metabolism in man, Ann. N.Y. Acad. Sci., 179: 704-722, 1971.

1248. Kutt, H., Diphenylhydantoin interactions with other drugs in man, Antiepileptic Drugs, 169-180, Woodbury, D. M., Penry, 1. K., and Schmidt, R. P., Eds., Raven Press, New York, 1972. (cf. Evans, et al., Lancet, 517, 1970.)

1249. Kutt, H., Diphenylhydantion relation of plasma levels to clinical control, Antiepileptic Drugs, 211-218, Woodbury, D. M., Penry, J. K., and Schmidt, R. P., Eds., Raven Press, New York, 1972.

1250. Kutt, H., Haynes, J., Verebely, K. and McDowell, F., The effect of phenobarbital on plasma diphenylhydantoin level and metabolism in man and rat liver microsomes, Epilepsy Abstracts, 3: 4, 1970.

1251. Kutt, H., Waters, L., and Fouts, J. R., Diphenylhydantoin-induced difference spectra with rat-liver microsomes, Chem. Biol. Interactions, 2: 195-202, 1970.

1252. Kutt, H., Waters, L., and Fouts, J. R., The effects of some stimulators (inducers) of hepatic microsomal drug-metabolizing enzyme activity on substrate-induced difference spectra in rat liver microsomes, J. Pharmacol. Exp. Ther., 179: 101-113, 1971.

1253. Kwalick, D. S., Anticonvulsants and DDT residues, JAMA, 215: 120-121, 1971.

1254. Kyosola, K., Abdominal epilepsy, Ann. Chir. Gyanaec. Fenn., 62: 101-103, 1973.

1255. Umprecht, F., Epilepsy and schizophrenia: a neurochemical bridge, Epilepsy Abstracts, 7: 190, 1974.

1256. Landolt, A. M., Treatment of acute post-operative inappropriate antidiuretic hormone secretion with diphenylhydantoin, Acta Endocr., 76: 625-628, 1974.

1257. Larsen, P. R., Atkinson, A. J., Wellman, H. N., and Goldsmith, R. E., Effect of diphenylhydantoin on thyroxine metabolism in man, J.  Clin. Invest., 49: 1266-1279, 1970.

1258. Lascelles, P. T., Kocen, R. S., and Reynolds, E. H., The distribution of plasma phenytoin levels in epileptic patients, J. Neurol. Neurosurg. Psychiat., 33: 501-505, 1970.

1259. Lasser, R. P., Management of arrhythmia, New York J. Med., 73: 1775-1777, 1973.

1260. Latham, A. N., Millbank, L., Richens, A., and Rowe, D. J. F., Liver enzyme induction by anticonvulsant drugs, and its relationship to disturbed calcium and folic acid metabolism, J. Clin. Pharmacol., 13: 337-342, 1973.

1261. Lawrence.T., Antiarrhythmic drugs,Topics on Medicinal Chemistry, 3:360-363, Wiley-Interscience, New York, 1970.

1262. Lee, S. 1. and Bass, N. H., Microassay of diphenylbydantoin: blood and regional brain concentrations in rats during acute intoxication, Neurology, 20: 115-124, 1970.

1263. Lefebvre, E. B., Haining, R. G., and Labbe, R. F., Coarse facies, calvarial thickening and hyperphosphatasia associated with long-term anticonvulsant therapy, New Eng. J. Med., 286: 1301-1302, 1972. (cf. Falcone and Davidson, Lancet, 2: 1112, 1973, Griscom, New Eng. J. Med., 287: 722, 1972, Lefebvre, et al., Nellhaus and Poskanzer, ibid.)

1264. Lesbre, J. P., Cathala, B., Salvador, M., Florio, R. Lescure, F., and Meriel, P., Diphenylhydantoin and digitalis toxicity, Arch. Mal. Coeur., 62: 412-437, 1969.

1265. Lesne, M., Sturbois, X. and Wilmotte, L., Modifications by diphenylhydantoin of the pharmacokinetic of digitoxin in the rat, J. Pharmacol., 5: 75-86, 1974.

1266. Letteri, 1. M., Melik, H., Louis, S., Kutt, H., Durante, P., and Glazko, A., Diphenylhydantoin metabolism in uremia, New Eng. J. Med., 285: 648-652, 197 1.

1267. LeVan, H., Gordon, P., and Stefani, S., Enhancement of radioresistance in mice treated with diphenylhydantoin, J. Pharm. Sci., 59: 1178-1179, 1970.

1268. LeVan, H., Gordon, P., and Stefani, S., Effect of diphenylhydantoin on survival and morphology of Ehrlich ascites tumor mice, Oncology, 26: 25-32, 1972.

1269. Levin, S. R., Booker, J., Smith, D. F., and Grodsky, G. M., Inhibition of insulin secretion by diphenylhydantoin in the isolated perfused pancreas, J. Clin. Endocr., 300: 400-401, 1970.

1270. Levin, S. R., Charles, M. A., O’Connor, M., and Grod sky, G. M., Use of diphenylhydantoin and diazoxide to investigate insulin secretary mechanisms, Presented at the 8th Congress of International Diabetes,5 Federation, Brussels, Belgium, 1973.

1271. Levin, S. R., Charles, M. A., O’Connor, M., Hagura, R., Smith, D., and Grodsky, G. M., Comparative effects of diphenylhydantoin (DPH) and diazoxide (DZ) upon biphasic insulin secretion from the isolated, perfused rat pancreas, with computerized correlation of biologic responses. Presented at the 8th Congress of International Diabetes Federation, Brussels, Belgium, 1973.

1272. Levin, S. R., Grodsky, G., Hagura, R., Smith, D., Licko, V., and Forsham, P., Comparison of effects of diphenylhydantoin and diazoxide on insulin secretion in the isolated perfused rat pancreas, using computerized correlation of experimental data, Clin. Res., 19: 375, 1971.

1273. Levin, S. R., Grodsky, G. M., Hagura, R., and Smith, D., Comparison of the inhibitory effects of diphenylhydantoin and diazoxide upon insulin secretion from the isolated perfused pancreas, Diabetes, 21: 856-862, 1972. (cf. Goldberg, Diabetes, 18: 101, 1969.)

1274. Levin, S. R., Reed, J. W., Ching, K. N., Davis, J. W., and Blum, R., Inhibition of insulin secretion after diphenylhydantoin (DPH) in diabetes and in obesity, Clin. Res., 20: 178, 1972.

1275. Levin, S. R., Reed, J. W., Ching, K. N., Davis, J. W., Blum, M. R., and Forsham, P. H., Diphenylhydantion: its use in detecting early insulin secretary defects in, patients with mild glucose intolerance, Diabetes, 22: 194-201, 1973.

1276. Levine, M. C., Reactions to anticonvulsants, New Eng. Med., 286: 1217, 1972.

1277. Levitt, B., Raines, A., Sohn, Y. J., Standaert, F. G., and Hirshfeld, J. W., The nervous system as a site of action for digitalis and antiarrhythmic drugs, Mt. Sinai Med. J., 37: 227-240, 1970.

1278. Levitt, M., Nixon, P.F., Pincus, J.H.,and Bertino, J.R., Transport characteristics of folates in cerebrospinal fluid; a study utilizing doubly labeled 5-methyltetrahydrofolate and 5-formyltetrahydrofolate, J. Clin. Invest., 50: 1301-1308, 197 1.

1279. Levo, Y., The protective effect of hydantoin treatment on carcinogenesis, Naunyn-Schmiedeberg’s Arch. Pharmacol., 285: 29-30, 1974.

1280. Levy, J. A., Wittig, E. O., Ferraz, E. C. F., Scleroderma associated with continuous electro-muscular activity, Arq. NeuroPsiquiat., 23: 283-287, 1965.

1281. Levy, R. H., and Smith, G. H., Dosage regimens of antiarrhythmics, Part 1: Pharmacokinetic properties, Amer. J. Hosp. Pharm., 30: 398-404, 1973.

1282. Lew, G. M., Increased hypothalamic norepinephrine in genetically hypertensive rats following administration of diphenylhydantoin, Proc. Soc. Exp. Biol. Med., 148: 30-32, 1975.

1283. Lewin, E. and Bieck, V., The effect of diphenylhydantoin administration on sodium-potassium-activated ATPase in cortex, Neurology, 21: 647-651, 1971.

1284. Lewin, E. and Bieck, V., The effect of diphenylhydantoin administration on cortex potassium-activated phosphatase, Neurology, 21: 417-418, 1971.

1285. Lewin, E., Charles, G., and McCrimmon, A., Discharging cortical lesions produced by freezing-the effect of anticonvulsants on sodium-potassium-activated ATPase, sodium, and potassium in cortex, Neurology, 19: 565-569, 1969.

1286. Lien, E. J., and Gudauskas, G. A., Structure side-effect sorting of drugs-1: Extrapyramidal syndrome, J. Pharm. Sci., 62: 645-647, 1973.

1287. Lifshitz, F. and Maclaren, N. K., Vitamin D-dependent rickets in institutionalized, mentally retarded children receiving long-term anticonvulsant therapy, J. Pediat., 83: 612-620, 1973.

1288. Lightfoot, R. W., Jr., and Christian, C. L., Serum protein binding of thyroxine and diphenylhydantoin, J. Clin. Endocr., 26: 305-308, 1966.

1289. Linde, L. M., Turner, S. W., and Awa, S., Present status and treatment of paroxysmal supraventricular tachycardia, Pediatrics, 50: 127-130, 1972.

1290. Lipicky, R. J., Gilbert, D. L., and Stillman, 1. M., The effects of diphenylhydantoin on voltage-dependent currents of the squid axon, Fed. Proc., 30: Abstract 65, 197 1.

1291. Lipicky, R. J., Gilbert, D. L., and Stillman, I. M., Diphenylhydantoin inhibition of sodium conductance in squid giant axon, Proc. Nat. Acad. Sci., 69: 1758-1760, 1972.

1292. Lisak, R. P., Lebeau, J., Tucker, S. H, and Rowland, L. P., Hyperkalemic periodic paralysis and cardiac arrhythmia, Neurology, 22: 810-815, 1972.

1293. Livingston, S., Abdominal pain as a manifestation of epilepsy (abdominal epilepsy) in children. J. Pediat., 38: 687-695, 1951.

1294. Livingston, S. and Livingston, H. L., Diphenylhydantoin gingival hyperplasia, Amer. J. Dis. Child., 117: 265-270, 1969.

1295. Livingston, S. and Pauli, L. L., Diphenylhydantoin and blood dyscrasias, JAMA, 320: 211-212, 1974.

1296. Livingston, S., Berman, W., and Pauli, L. L., Anticonvulsant drugs and vitamin D metabolism, JAMA, 224: 1634-1635, 1973.

1297. Livingston, S., Berman, W., and Pauli, L. L., Anticonvulsant drugs and vitamin D metabolism, JAMA, 226: 787, 1973.

1298. Livingston, S., Berman, W., and Pauli, L. L., Maternal epilepsy and abnormalities of the fetus and newborn, Lancet, 2: 1265, 1973.

1299. Lockman, L. A., Hunninghake, D. B., Krivit, W., and Desnick, R. J., Relief of pain of Fabry’s disease by diphenylhydantoin, Neurology, 23: 871-875, 1973.

1300. Lockman, L. A., Krivit, W., and Desnick, R. J., Relief of the painful crises of Fabry’s disease by diphenylhydantoin, Neurology, 21: 423, 197 1.

1301. Loeser, J. D., Neuralgia, Postgrad. Med., 53: 207-210, 1973.

1302. Lohrenz, 1. G., Levy, L., and Davis, J. F., Schizophrenia or epilepsy? A problem in differential diagnosis, Compr. Psychiat., 3: 54-62, 1962.

1303. Longshaw, R. N., Inhibition of hepatic drug metabolism, Drug Intelligence and Clinical Pharmacy, 7: 263-270, 1973.

1304. Looker, A. and Conners, C. K., Diphenylhydantoin in children with severe temper tantrums, Arch. Gen. Psychiat., 23: 80-89, 1970.

1305. Loong, S. C. and Ong, Y. Y., Paroxysmal kinesigenic choreoathetosis, J. Neurol. Neurosurg. Psychiat., 36: 921-924, 1973.

1306. Lotti, V. J., Torchiana, M. L., and Porter, C. C., Investigations on the action and mechanism of action of diphenylhydantoin as an antagonist of tetrabenazine and reserpine, Arch. Int. Pharmacodyn., 203: 107-116, 1973.

1307. Lotto, A., Sanna, G. P., Bossi, M., and Lomanto, B., New therapeutic aspects of ventricular arrhythmias, Cardiol. Prat., 22: 1-15, 1971.

1308. Louis, S., Kutt, H. and McDowell, F., Modification of experimental seizures and anticonvulsant efficacy by peripheral stimulation, Neurology, 21: 329-336, 1971.

1309. Lovell, R. R. H., Mitchell. M. E., Prineas, R. J., Sloman, J. G., Vajda, F. J., Pitt, A., Habersberger, P., Rosenbaum, M., Nestel, P. J., Goodman, H. T., and Sowry, G. S. C., Phenytoin after recovery from myocardial infarction-controlled trial in 568 patients, Lancet, 1055-1057, 1971.

1310. Lowe, C. R., Congenital malformations among infants born to epileptic women, Lancet, 9-10, 1973. (cf. Marsh and Fraser, Teratology, 7: A-23, 1973.)

1311. Lown, B., Temte, J. V. and Arter, W. J., Ventricular tachyarrhythmiasè:clinical aspects, Circulation, 47: 1364-1381, 1973.

1312. Lucchesi, B. R., The pharmacology and clinical uses of antiarrhythmic drugs, U. Michigan Med. Cent. J., 37: 61-73, 1971.

1313. Ludtke, A. H., Autenrieth, G., and Dankert, D., On the effects of diphenylhydantoin, potassium-magnesium-asparaginate, insulin and female sex hormones on the hypothermic fibrillation threshold of the guinea-pig heart, Arzneimittelforschung, 20: 1554-1557, 1970.

1314. Lund, L., Berlin, A., and Lunde, K. M., Plasma protein binding of diphenylhydantoin in patients with epilepsy, Clin. Phamacol. Ther., 13: 196-200, 1972.

1315. Lunde, K. M., Plasma protein binding of diphenylbydantoin in man, Acia Pharmacol., 29: 152-155, 197 1.

1316. Lunde, K. M., Rane, A., Yaffe, S. J., Lund, L., and Sjoqvist, F., Plasma protein binding of diphenylhydantoin in man, Clin. Pharmacol. Ther., II: 846-855, 1970.

1317. Lund, L., Lunde, P. K., Rane, A., Borga, O. and Sjoqvist, F., Plasma protein binding, plasma concentrations, and effects of diphenylhydantoin in man, Ann. N.Y. Arad. Sci., 179: 723-728, 1972.

1318. Lussier-Uzaroff, J. and Fletcher, B. D., Rickets and anticonvulsant therapy in children: a roentgenologic investigation, J. Canad. Assn. Radial., 22: 144-147, 1971.

1319. Lutz, E. G., Add vitamins to DPH, urges doctor, National Spokesman, 6: 7, 1973.

1320. Lutz, E. G., On vitamins and anticonvulsants, Medical World News, 3, 1973.

1321. Mace, J., and Schneider, S., Diphenylhydantoin and rickets, Lancet, 1119, 1973.

1322. MacGee, J., The rapid determination of diphenylhydantoin in blood plasma by gas-liquid chromatography, Med. Res. Lab., V.A. Hosp. and Dept. Bio. Chem. and Exp. Med., Cincinnati, Ohio, 1970.

1323. MacKinney, A. A. and Booker, H. E., Diphenylhydantoin effects on human lymphocytes in vitro and in vivo, Arch. Inmm. Med., 129: 988-992, 1972.

1324. MacKinney, A. A. and Vyas, R., Diphenylhydantoininduced inhibition of nucleic acid synthesis in cultured human lymphocytes, Proc. Soc. Exp. BW. Med., 141: 89-92, 1972.

1325. Mackinney, A. A. and Vyas, R., The assay of diphenylhydantoin effects on growing human lymphocytes, J. Pharmacol. Exp. Ther., 186: 37-43, 1973.

1326. Maclaren, N. and Ufshitz, F., Vitamin D-dependency rickets in institutionalized, mentally retarded children on long term anticonvulsant therapy. 11. The response to 25-hydroxycholecalciferol and to vitamin D, Pediat. Res., 7: 914-922, 1973.

1327. Madsen, S. N., Hansen, J. M. and Deckert, T., Intravenous glucose tolerance during treatment with phenytoin, Acta Neurol. Scand., 50: 257-260, 1974.

1328. Maletzky, B. M. and Klotter, J., Episodic dyscontrol: A controlled replication, Dis. Nerv. Syst., 35: 175-179, 1974.

1329. Maletzky, B. M., Treatable violence, Med. Times, 100: 74-79, 1972.

1330. Malherbe, C., Burrill, K. C., Levin, S. R., Karam, J. H., and Forsham, P. H., Effect of diphenylhydantoin on insulin secretion in man, New Eng. J. Med., 286: 339-342, 1972.

1331. Markkanen, T., Himanen, P., Pajula, R. L., and Molnar, G., Binding of folic acid to serum proteins, Acia Haemat., 50: 284292, 1973.

1332. Markkanen, T., Peltola, O., Himanen, P. and Rickkinen, P., Metabolites of diphenylhydantoin in human plasma inhibits the pentose phosphate pathway of leukocytes, Pharmacology, 6: 216-222, 1971.

1333. Martin, C. M., Reliability in product performance in an innovative environment, The Economics of Drug Innovation, 63-82, Cooper, J. D., Ed., The Proceedings of the First Seminar of Economics of Pharmaceutical Innovation, 1969.

1334. Martin, W. and Rickers, J., Cholestatic hepatogis induced by diphenylhydantoin. Case report and review of literature, Wien. Klin. Wschr., 84: 41-45, 1972.

1335. Mason, D. T., Amsterdam, E. A., Massumi, R. A., and Zelis, R., Recent advances in antiarrhythmic drugs: clinical pharmacology and therapeutics, The Acute Cardiac Emergency-Diagnosis and Management, 95-123, Eliot, R. S., Ed., Futura Publishing, Mount Kisco, New York, 1972.

1336. Mason, D. T., DeMaria, A. N., Amsterdam, E. A., Zelis, R., and Massurni, R. A., Antiarrhythmic agents. 11: Therapeutic consideration, Drugs, 5: 292-317, 1973.

1337. Mason, D. T., DeMaria, A. N., Amsterdam, E. A., Zelis, R., and Massumi, R. A., Antiarrhythmic agents. 1: Mechanisms of action and clinical pharmacology, Drugs, 5: 261-291, 1973.

1338. Mason, D. T., Spann, J. F. Jr., Zelis, R., and Amsterdam, E. A., Evolving concepts in the clinical pharmacology and therapeutic uses of the antiarrhythmic drugs, Cardiovascular Therapy, The Art and the Science, 122-137, Russek, H. 1. and Zohman, B. L., Eds., The Williams & Wilkins Co, Baltimore, 1971.

1339. Mathur, K. S., Wahal, P. K., Seth, H. C. and Hazra, D. K., Diphenylhydantoin sodium in cardiac arrhythmias, J. Indian Med. Assoc., 57: 256-258, 1971.

1340. Matsuzaki, M. and Killam, K. F., Alterations in conditional behavioral and electrographic responses to interrupted visual stimuli following repeated doses of diphenylhydantoin, Fed. Proc., 30: Abstract 483, 197 1.

1341. Mattes, L. M., Spritzer, R. C., Nevins, M. A., Weisenseel, A. C., Donoso, E., and Friedburg, C. K., The cardiovascular effects of diphenylhydantoin in patients with cardiac pacemakers, Circulation, 37-38 (Suppl. 6): 135, 1968.

1342. Matthews, W. B., Tonic seizures in disseminated sclerosis, Brain, 81: 193-206, 1958.

1343. Matthews, W. D. and Connor, J. D., Effects of diphenylhydantoin on interhippocampal evoked responses, Pharmacologist, 16: 228, 1974.

1344. Mattson, R. H., Gallagher, B. B., Reynolds, E. H., and Glass, D., Folate therapy in epilepsy, Arch. Neural., 29: 78-81, 1973.

1345. McAllister, R. G., Jr., The possible role of antiarrhythmic drugs in the prevention of sudden death, Heart and Lung, 2: 857-861, 1973.

1346. McCabe, B. F., Chronic burning tongue syndrome, Ann. Otol. Rhinol. Laiyngol., 83: 264, 1974.

1347. McCabe, W. S., and Habovick, J. A., Thorazine as an epileptogenic agent, Amer. J. Psychiat., 120: 595-597, 1963.

1348. Mcllvanie, S. K., Phenytoin and depression of immunological function, Lancet, 323, February, 1972.

1349. McQueen, E. G., Owen, D., and Ferry, D. G., Effect of phenytoin and other drugs in reducing serum DDT levels, New Zeal. Med. J., 75: 208-211, 1972.

1350. Meadow, S. R., Anticonvulsant drugs and congenital abnormalities, Lancet, 2: 1296, 1968.

1351. Meikle, W., Jubiz, W., West, C. D., and Tyler, F. H., Effect of diphenylhydantoin (Dilantin) on the metyrapone test demonstrated by a new assay for plasma metyrapone, Clin. Res., 17: 107, 1969.

1352. Melikian, V., Eddy, J. D., and Paton, A., The stimulant effect of drugs on indocyanine green clearance by the liver, Gut, 13: 755-758, 1972.

1353. Mendelson, J. H., Biologic concomitants of alcoholism, New Eng. J. Med., 283: 24-32, 1970.

1354. Mennear, J. H. and Gossel, T. A., Inhibitory effect of diphenylhydantoin on the diabetogenic action of alloxan in the mouse, Diabetes, 21: 80-83, 1972.

1355. Mennear, J. H., and Gossel, T. A., Interactions between diphenylhydantoin and tolbutamide in mice, Toxic. Appl. Pharmacol., 24: 309-316,1973.

1356. Meyer, J. G., The teratological effects of anticonvulsants and the effects on pregnancy and birth, Europ. Neurol. 10: 179-190, 1973.

1357. Meyer, J. S., Binns, P. M., Ericsson, A. D., and Vulpe, M., Sphenopalatine ganglionectomy for cluster headache, Arch. Otolaryng., 92: 475-484, 1970.

1358. Michell, A. R., The effect of diphenylhydantoin on sodium appetite in rats, J. Physiol., 237: 53-55,1973.

1359. Mick, B. A., Diphenylhydantoin and intermittent edema, JAMA, 225: 1533, 1973.

1360. Miley, C. E. and Forster, F. M., Paroxysmal signs and symptoms in multiple sclerosis, Neurology, 24: 458-461, 1974.

1361. Millichap, J. G., Clinical efficacy and usage of anticonvulsants, Chemical Modulation of Brain Function, 199205, Sabelli, H. C., Ed., Raven Press, New York, 1973.

1362. Millichap, J. G., Drugs in management of minimal brain dysfunction, Ann. N.Y. Acad. Sci., 205: 321-334, 1973.

1363. Millichap, J. G., Efficacy, therapeutic regimens of drugs to control hyperkinesis in children with minimal brain dysfunction reported from trials, Drug Res. Rep., 15: S5-S11, 1972.

1364. Mirkin, B. L. and Wright, F., Drug interactions: effect of methylphenidate on the disposition of diphenylhydantoin in man, Neurology, 21; 1123-1128, 197 1.

1365. Mirkin, B. L., Diphenylhydantoin: placental transport, fetal localization, neonatal metabolism, and possible teratogenic effects, J. Pediat., 78: 329-337, 1971.

1366. Mirkin, B. L., Maternal and fetal distribution of drugs in pregnancy, Clin. Phamacol. Ther., 14: 643-647, 1973.

1367. Mirkin, B. L., Placental transfer and neonatal elimination of diphenylhydantoin, Amer. J. Obstet. Gynee., 109: 930-933, 1971.

1368. Mittler, J. C. and Glick, S. M., Radioimmunoassayable oxytocin release from isolated neural lobes: responses to ions and drugs, Abstracts Fourth lnt. Cong. Endocr., 47, June, 1972.

1369. Mladinich, E. K., Diphenylhydantoin in the Wallenberg syndrome, JAMA, 230: 372-373, 1974.

1370. Monson, R. R., Rosenberg, L., Hartz, S. C., Shapiro, S., Heinonen, O. P., and Slone, D., Diphenylhydantoin and selected congenital malformations, New Eng. J. Med., 289: 1050-1052, 1973.

1371. Morgan, R. J., Scleroderma: treatment with diphenylhydantoin, Cutis, 8: 278-282, 1971.

1372. Moss, A. J. and Patton, R. D., Dipheriylhydantoin, comparison of antiarrhythmic agents, and management of refractory arrhythmias, Antiarrhythmic Agents, 52-58, 101-115, Charles C Thomas, Springfield, Ill., 1973.

1373. Moss,G.andStein,A.A.,Cerebraletiologyoftheshock lung syndrome: protective effect of diphenylhydantoin, Personal Communication, 1972.

1374. Moss, G., Shock, cerebral hypoxia and pulmonary vascular control: the centri-neurogenic etiology of the “respiratory distress syndrome”, Bull. N.Y. Acad. Med., 49: 689, 1973.

1375. Mountain, K. R., Hirsh, J., and Gallus, A. S., Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy, Lancet, 1: 265-268, 1970. (cf. Davies, Lancet, 1: 413, 1970.)

1376. Mouravieff-Lesuisse, F. and Giurgea, C., Influence of electro-convulsive shock on the fixation of an experience at spinal level, Arch. Int. Pharmuodyn., 183: 410-411, 1970.

1377. Nabwangu, J. F., Head injury, E. Afr. Med. J., 49: 624629, 1972.

1378. Narisawal K., Honda, Y., and Arakawa, T., Effect of diphenylhydantoin administration on single carbon metabolism in folate deficient rats, Tohoku, J. Exp. Med., 110: 359-365, 1973.

1379. Nasello, A. G., Montini, E. E., and Astrada, C. A., Effect of veratrine, tetraethylammonium and diphenyihydantoin on potassium release by rat hippocampus, Pharmacology, 7: 89-95, 1972.

1380. Negri, S., An atypical case of Steinert’s disease (myotonia dystrophica) in infancy, Confin. Neurol., 33: 323-333, 1971.

1381. Neville, B. G. R., The origin of infantile spasms: evidence from a case of hydranencephaly, Epilepsy Abstracts, 6: 179, 1973.

1382. Newtown, R., Amitriptyline and imipramine poisoning in children, Brit. Med. J., 2: 176, 1974.

1383. Nielsen, T. and Cotman, C., The binding of diphenylhydantoin to brain and subcellular fractions, Europ. J. Pharmacol., 14: 344-350, 1971.

1384. Niswander, J. D. and Wertelecki, W., Congenital malformation among offspring of epileptic women, Lancet, 1062, May, 1973.

1385. Noach, E. L., VanRees, H. and DeWolff, F. A., Effects of Diphenylhydantoin (DPH) on absorptive processes in the rat jejunum, Archives Internationales de Pharmacodynamie et de Therapie, 206: 392-393, 1973.

1386. Norris,j. W. and Pratt, R. F., A controlled study of folic acid in epilepsy, Neurology, 21: 659-664, 197 1.

1387. Nuki, K. and Cooper, S. H., The role of inflammation in the pathogenesis of gingival enlargement during the administration of diphenylhydantoin sodium in cats, J. Periodont. Res., 7: 102-110,1972.

1388. O’Leary, J. A., Feldman, M., and Switzer, H. E., Phenobarbital-Dilantin treatment of the intrauterine patient, J. Reprod. Med., 5: 81-83, 1970.

1389. O’Malley, W. E., Denckla, M. B., and O’Doherty, D. S., Oral absorption of diphenylhydantoin as measured by gas liquid chromatography, Epilepsy Abstracts, 3: 230, 1970.

1390. O’Reilly, M. V. and MacDonald, R. T., Efficacy of phenytoin in the management of ventricular arrhythmias induced by hypokalaemia, Brit. Heart J., 35: 631-634, 1973.

1391. Oates, R. K. and Tonge, R. E., Phenytoin and the pseudolvmphoma syndrome, Med. J. Aust., 371-373, 1971.

1392. Obbens, E. A., Experimental epilepsy induced by folate derivatives, Epilepsy Abstracts, 6: 221-222, 1973.

1393. Odar-Cederlof, I. and Borga, O., Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding, Europ. J. Clin. Phartnacol., 7: 31-37, 1974.

1394. Oge, V., Drug therapy in alcoholism, Ill. Med. J., 139: 606-610, 1971.

1395. Olds, M. E., Comparative effects of amphetamine, scopolamine, chlordiazepoxide, and diphenylliydantoin on operant and extinction behavior with brain stimulation and food reward, Neuropharmacology, 9: 519-532, 1970.

1396. Osorio, C., Jackson, D. J., Gartside, J. M., and Goolden, A. W. G., Effect of carbon dioxide and diphenylhydantoin on the partition of triiodothyronine labelled with iodine-131 between the red cells and plasma proteins, Nature, 196: 275-276, 1962.

1397. Overall, 1. E., Brown, D., Williams, J. D., and Neill, L. T., Drug treatment of anxiety and depression in detoxified alcoholic patients, Arch. Gen. Psychiat., 29: 218-221, 1973.

1398. Pakszys, W. and D@omzal, T., Ceruloplasmin stimulation test, Epilepsy Abstracts, 7: 107, 1974.

1399. Pakszys, W., Phenytoin, Epilepsy Abstracts, 6: 236, 1973.

1400. Parisi, A. F. and Raines, A., Diphenylhydantoin suppression of repetitive activity generated in nerve endings, Fed. Proc., Abstract 22: 390, 1963.

1401. Pashayan, H., Pruzansky, D., and Fruzansky, S., Are anticonvulsants teratogenic?, Lancet, 702-703, 197 1.

1402. Patton, R. D., and Helfant, R. H., Atrial flutter with one-to-one conduction, Dis. Chest, 55: 250-251, 1969.

1403. Payen, J., A study of changes in the gum during treatment with diphenylhydantoin sodium, Rev. Odonto-Stomatol., 19: 47-53, 1972.

1404. Pelkonen, R. and Taskinen, M. R., Effect of diphenylhydantoin on plasma-insulin in insulinoma, Lancet, 604-605, 1973.

1405. Pento, J. T., Glick, S. M., and Kagan, A., Diphenylhydantoin inhibition of glucagonan- calcium-stimulated calcitonin release, Fed. Proc., Abstract 31: 251, 1972.

1406. Pento, J. T., Glick, S. M., and Kagan, A., Diphenylhydantoin inhibition of calcitonin secretion in the pig. Endocrinology, 92: 330-333, 1973.

1407. Penttila, O., Neuvonen, P. J., Aho, K. and Lehtovaara, R., Interaction between doxycycline and some antiepileptic drugs, Brit. Med. J., 2: 470-472, 1974.

1408. Persijn, G. G. and Van Zeben, W., Generalized lymphadenopathy caused by phenytoin in a six-year-old child, Epilepsy Abstracts, 6: 236, 1973.

1409. Peter, J. B., A (Na’ + K’) ATPase of sarcolemma from skeletal muscle, Biochem. Biophys. Res. Commun., 40: 1362-1367, 1970.

1410. Peters, B. H. and Samaan, N. A., Hyperglycemia with relative hypoinsulinemia in diphenylhydantoin toxicity, New Eng. J. Med., 281: 91-92, 1969.

1411. Petroski, D. and Patel, A. N., Diphenylhydantoin for intractable hiccups, Lancet, 1: 739, 1974.

1412. Pezcon, J. D., and Grant, W. M., Sedatives, stimulants, and intraocular pressure in glaucoma, Arch. Ophthal., 72: 177188, 1964.

1413. Pezzimenti, J. F. and Hahn, A. L., Anicteric hepatitis induced by diphenylhydantoin, Arch. Inkm. Med., 125: 118-120, 1970.

1414. Phillips, J. R. and Eldridge. F. L., Respiratory myoclonus (Leeuwenhoek’s disease), New Eng. J. Med., 289: 13901395. 1973.

1415. Pinto, A., Simopoulos, A. M., Uhlenhuth, E. H. and De Rosa, E. R., Responses of chronic schizophrenic females to a combination of diphenylhydantoin and neuroleptics: a double-blind study, Comprehensive Psychiatry, 16(6): 529-536, 1975.

1416. Pincus, J. H. and Lee, S. H., Diphenylhydantoin and norepinephrine release, Neurology, 22: 410, 1972.

1417. Pincus, J. H., and Lee, S. H., Diphenylhydantoin and calcium in relation to norepinephrine release from brain slices, Arch. Neurol., 29: 239-244, 1973.

1418. Pincus, J. H., Diphenylhydantoin and ion flux in lobster nerve, Arch. Neurol., 26: 4-10, 1972.

1419. Pincus, J. H., Grove, I., Marino. B. B. and Glaser, G. E., Studies on the mechanism of action of diphenylhydantoin, Presented at the International Soc. Neurochem., September, 1969.

1420. Pinkhas, J., Ben-Bassat, M., and DeVries, A., Death in anticonvulsant-induced megaloblastic anemia, JAMA, 224: 246, 1973.

1421. Podos, S. M., Becker, B., Beaty, C., and Cooper, D. G., Diphenylhydantoin and cortisol metabolism in glaucoma, Amer J. Ophthal., 74: 498-500, 1972.

1422. Podos, S. M., Glaucoma, Invest. Ophthal., 12: 3-4, 1973,

1423. Poley, J. R., and Bhatia, M., Recurrent abdominal pain: recurrent controversy, Pediatrics, 52: 144-145, 1973.

1424. Pollen, R. H., Cat-scratch encephalitis, Neurology, 18: 1031-1033, 1968.

1425. Porciello, P. 1. and Zanini, S., Diphenylhydantoin: antiarrhythmic drug, Fracastoro, 64: 114-135, 197 1.

1426. Porciello, P. I., Zanini, S., and Poppi, A., Comparative considerations on two modern antiarrhythmic drugs: lidocaine and diphenylhydantoin, G. Ital. Cardiol. 2: 579-583, 1972.

1427. Poschel, B. P. H., A simple and specific screen for benzodiazepine-like drugs, Psychoparmacologia, 19: 193-198, 1971.

1428. Postlethwaite, R. J. and Price, D. A., Amitriptyline and imiprarnine poisoning in children, Brit. Med. J., 2: 504, 1974.

1429. Preston, T. A., Yates, J. D., and Brymer, J. F., Three therapeutic approaches in tachycardia, Geriatrics, 28: 110-116, 1973.

1430. Price, D. A. and Postiethwaite, J. R., Amitriptyline and imipramine poisoning in children, Brit. Med. J., 1: 575, 1974.

1431. Pryles, C. V., Livingston, S. and Ford, F. R., Familial paroxysmal choreoathetosis of Mount and Reback, Pediatrics, 9: 44-47, 1952.

1432. Puri, P. S., The effect of diphenylhydantoin sodium (Dilantin) on myocardial contractility and hemodynamics, Amer. Heart J., 82: 62-68, 1971.

1433. Puro, D. G. and Woodward, D. J., Effects of diphenylhydantoin on activity of rat cerebellar Purkinje cells, Neuropharmacology, 12: 433-440, 1973.

1434. Quiret, J. C., Bens, J. L., Duboisset, M., Lesbre, P. and Bernasconi, P., Diphenylhydantoin injectable in cardiology, Arch. Mal. Coeur., 67: 87-96, 1974.

1435. Raines, A. and Standaert, F. G., Effects of anticonvuisant drugs on nerve terminals, Epilepsia, 10: 211-227, 1969.

1436. Raines, A., Levitt, B., Standaert, F. G. and Sohn, Y. The influence of sympathetic nervous activity on the antiarrhythmic efficacy of diphenylhydantoin, Europ. J. Pharmacol ., I 1: 293-297, 1970.

1437. Raines, A., Sohn, Y.J., and Levitt, B., Spinal excitatory and depressant effects of sodium diphenylthiohydantoinate, J. Pharmacol. Exp. Ther., 177: 350-359, 1971.

1438. Raines, A., Effects of diphenylhydantoin on post-tetanic alterations in the terminals of dorsal root fibers and motor nerves, Georgetown University Doctoral Thesis, June, 1965.

1439. Ralston, A. J., Snaith, R. P., and Hinley, J. B., Effects of folic acid on fit-frequency and behaviour in epileptics on anticonvulsants, Lancet, 1: 867-868, 1970.

1440. Ramdohr, Von B., Schuren, K. P., Dennert, J., Macha, H.-N. and Schroder, R., Influence of diphenylhydantoin on hemodynamics in recent myocardial infarct., Verhandlungen der Deutschen Gesellschaft Kreislaufforschung, 35: 444-50, 1969.

1441. Rane, A., Garle, M., Borga, O., Sjoqvist, F., Plasma disappearance of transplacentally transferred diphenylhydantoin in the newborn studied with mass fragmentography, Clin. Pharmacol . Ther. 15: 39-45, 1974.

1442. Rane, A., Lunde, P. K. M., Jalling, B., et al., Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants, Epilepsy Abstracts, 4: 223, 1971.

1443. Rane, A., Urinary excretion of diphenyihydantoin metabolites in newborn infants, J. Pediat., 85: 543-545, 1974.

1444. Raskin, N. H., Levinson, S. A., Pickett, J. B., Hoffman, P. M., and Fields, H. L., Postsympathectomy neuralgia, Amer. Surg., 128: 75-78, 1974.

1445. Raskovic, J., Phenomenological aspects of the psychotic epileptic state in terms of therapeutic argument, Neuropsihiallya, 20: 161-166, 1972.

1446. Ray, A. K., and Rao, D. B., Calcium metabolism in elderly epileptic patients during anticonvulsant therapy, Epilepsy Abstracts, 7: 210, 1974.

1447. Raz, S., Zeigler, M., and Caine, M., The effect of diphenylhydantoin on the urethra, Invest. Urol., 10: 293-294, 1973.

1448. Reidenberg, M. M., Odar-Cederlof, I., Von Bahr, C., Borga, O., and Sjoqvist, F., Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function, New Eng. J. Med., 285: 264-267, 1971.

1449. Reimann, H. A., Abdominal epilepsy and migraine, JAMA, 224: 128,1973.

1450. Reimann, R., Lemmel, W., and Theisen, K., Efficacy and risks of diphenylhydantoin in cardiac arrhythmias, Munchen Med. Wschr., 113: 893-899, 1971.

1451. Reizenstein, P. and Lund, L., Effect of anticonvulsive drugs on folate absorption and the cerebrospinal folate pump, Epilepsy Abstracts, 7: 86, 1974.

1452. Remmer, H., Induction of drug metabolizing enzyme system in the liver, Europ. J. Clin. Pharmacol., 5: 116-136, 1972.

1453. Resnekov, L., Drug therapy before and after the electroversion of cardiac dysrhythmias, Progr. Cardiovasc. Dis., 16: 531-538, 1974.

1454. Rettura, G., Stamford, W. and Seifter, E., Reversal of cardiac calcification by diphenylhydantoin, Paper presented at N.E. Regional Meeting of the American Chemical Society, Oct. 1973.

1455. Reynolds, E. H., Anticonvulsant drugs, folic acid metabolism and schizophrenia-like psychoses in epilepsy, Psychische Storungen bei Epilepsie, H. Penin, Ed., F. K. Schattauer Veriag, Stuttgart-New York, 1973.

1456. Reynolds, E. H., Anticonvulsant drugs, folic acid metabolism, fit frequency and psychiatric illness, Psychiat. Neurot. Neuruchir., 74: 167-174, 1971.

1457. Reynolds, E. H., Anticonvulsants, folic acid and epilepsy, Lancet, 1376-1378, June, 1973. 1458. Reynolds, E. H., Chanarin, I., Milner, G. and Matthews, D. M., Anticonvulsant therapy, folic acid and vitamin B12 metabolism and mental symptoms, Epitepsia, 7: 261-270, 1966.

459. Reynolds, E. H., Mattson, R., and Gallagher, B., Relationships between serum and cerebrospinal fluid anticonvulsant drug and folic acid concentrations in epileptic patients, Neurology, 22: 841-844, 1972. 

1460. Reynolds, E. H., Streiff, R. R., Wilder, B. J., and Hammer, R. H., I)iphenylhydantoin hematologic aspects of toxicity, Antiepikptic Drugs, 247-266, Woodbury, D. M., Penry, J. K., and Schmidt, R. P., Eds., Raven Press, New York, 1972. (cf. Bottomley, et al., J. Mich. Dent. Ass., 53: 256, 1971 and Kolodzieczak and Prazanowski, Epilepsy Abstracts, 5: 149, 1972.)

1461. Reynolds, J. W. and Mirkin, B. L., Urinary corticosteroid and diphenylhydantoin metabolite patterns in neonates exposed to anticonvulsant drugs in utero, JAMA, 227: 577, 1974.

1462. Rhee, R. S., Margolin, M., and Pellock, J., Palatal myoclonus and diphenylhydantoin therapy, New Eng. J. Med., 290: 1088-1089, 1974.

1463. Richens, A. and Houghton, G. W., Phenytoin intoxication caused by sulthiame, Lancet, 1442-1443, 1973.

1464. Richens, A. and Rowe, D. J. F., Disturbance of calcium metabolism by anticonvulsant drugs, Brit. Med. J., 4: 73-76,1970.

1465. Richens, A. and Rowe. D. J. F., Anticonvulsant hypocalcemia, Epilepsy Abstracts, 5: 224, 1972.

1466. Riddell, D. and Leonard, B. E., Some properties of a coma producing material obtained from mammalian brain, Neuropharmacology, 9: 283-299, 1970.

1467. Riehl, J. L. and McIntyre, H. B., Acute effects of Dilantin on the EEG of epileptic patients: a quantitative study, Electroenceph. Clin. Neurophysiol., 28: 94, 1970.

1468. Rifkind, A. B., Gillette, P. N., Song, C. S., and Kappas, A., Drug stimulation of 8-Aminolevulinic acid synthetase and cytochrome P-450 in vivo in chick embryo liver, J. Pharmacol. Exp. Ther., 185: 214-225, 1973.

1469. Riker, W. F., The pharmacology of the neostigmine-like facilitatory drug effect at the mammalian neuromuscular junction, Jap. J. Pharmacol., 22: 1, 1972.

1470. Rish, B. L. and Caveness, W. F., Relation of prophylactic medication to the occurrence of early seizures following craniocerebral trauma, J. Neurosurg., 38: 155-158, 1973.

1471. Rizzo, M., Morselli, P. L. and Garattini, S., Further observations on the interactions between phenobarbital and diphenylhydantoin during chronic treatment in the rat, Biochem. Pharmacol., 21: 449-454, 1972.

1472. Robbins, M. M., Aplastic anemia secondary to anticonvulsants, Amer. J. Dis. Child., 104: 64-74, 1962.

1473. Roberts, E., An hypothesis suggesting that there is a defect in the GABA system in schizophrenia, Neurosciences Research Program Bulletin, 10: 468-482, 1972.

1474. Roberts, J., The effect of diphenylhydantoin on the response to accelerator nerve stimulation, Proc. Soc. Exp. Biol. Med., 134: 274-280, 1970.

1475. Robineaux, R., Lorans, G., and Beaure D’Augeres, C., Action of diphenylhydantoin on the growth and respiration of cell in culture, Rev. Europ. Etudes Clin. Biol., 15: 1066-1071, 1970.

1476. Rockliff, B. W., and Davis, E. H., Controlled sequential trials of carbamazepine in trigeminal neuralgia, Arch. Neurot., 15: 129-136,1966.

1477. Rodman, N. F., McDevitt, N. B., and Almond, J. R., Platelet function inhibition by diphenylhydantoin, Fed. Proc., 30: Abstract 513, 1971.

1478. Roman, 1. C. and Caratzali, A., Effects of anticonvulsant drugs on chromosomes, Brit. Med. J., 234, 1971.

1479. Romero, E., Marañon, A. and Bobillo, E. R., Antithyroid action of hydantoin derivatives, Rev. Iber. Endocr., 101: 363-375, 1970.

1480. Rose, L. I., Williams, G. H., Jagger, P. I., Lauler, D. P., and Thorn, G. W., The paradoxical dexamethasone response phenomenon, Metabolism, 18: 369-375, 1969.

1481. Rosenthal, J. E. and Cohen, L. S., Therapeutic predicament-the unresponsive PVC, Geriatrics, 28: 88-92, 1973.

1482. Ross, G. S., A technique to study pain in monkeys; effect of drugs and anatomic lesions, Henry Ford Hosp. Symposium an Pain, Chap. 8, 100-101, Knighton, R. S. and Dumke, P. R., Eds., Little, Brown and Co., Boston, 1966.

1483. Ross, G. S., Effect of diphenylhydantoin on experimental pain in the monkey, Neurology, 15: 275, 1965.

1484. Ross, L. M., Diphenyihydantoin (DPH) induced cleft palate, Teratology, 7: A-26, June, 1973.

1485. Rovin, S., Sabes, W. R., Eversole, L. R., and Gordon, H. A., Dilantin as a caries retarder, J. Dent. Res., 52: 267, 1973.

1486. Rubins, S., Lozano, J., Carrasco, H., Lang, T. W., and Corday, E., Tachyarrhythmias: Differential diagnosis and therapy after acute myocardial infarction, Geriatrics, 27: 123-133, 1972.

1487. Rudner, E. J., Diphenylhydantoin therapy, Arch. Dem., 102:561,1970.

1488. Rumack, B. H., Wolfe, R. R. and Gilfrich, H., Phenytoin (diphenylhydantoin) treatment of massive digoxin overdose, Brit. Heart J., 36: 405-408, 1974.

1489. Rundle, A. T. and Sudell, B., Leucine aminopeptidase isoenzyme changes after treatment with anticonvulsant drugs, Clin. Chim. Acta, 44: 377-384, 1973.

1490. Rushton, J. G., Medical treatment of trigeminal neuralgia, Med. Clin. N. Amer., 52: 797-800, 1968.

1491. Ruskin, H. M., Therapeutic Dilantin levels, New Eng. Med., 284: 792, 1971.

1492. Rutkowski, M. M., Cohen, S. N., and Doyle, E. F., Drug therapy of heart disease in pediatric patients. II. The treatment of congestive heart failure in infants and children with digitalis preparations, Amer. Heart J., 86: 270-275, 1973.

1493. Rutkowski, M. M., Doyle, E. F. and Cohen, S. N., Drug therapy of heart disease in pediatric patients III. The therapeutic challenge of supraventricular tachyarrhythmias in infants and children, Amer. Heart J., 86: 562-568, 1973.

1494. Rutledge, R., Sohn, Y. J., and Sardinas, A., Interaction of diphenylhydantoin and succinylcholine at the neuromuscular junction, Pharmacologist, 13: 265, 1971.

1495. Saad, S. F., El Masry, A. M., and Scott, P. M., Influence of certain anticonvulsants on the concentration of 8-aminobutyric acid in the cerebral hemispheres of mice, Communications in Behav. Biol., 9: February, 1972.

1496. Sabih, K. and Sabih, K., Combined GLC and high-resolution mass ‘spectroscopic analysis of diphenylhydantoin, J. Pham. Sci., 60: 1216-1220, 1971.

1497. Sampliner, R., Diphenylhydantoin control of alcohol withdrawal.seizures, JAMA, 230: 1430-1432, 1974.

1498. Sampson, D., Harasymiv, 1. and Hensley, W. J., Gas chromatographic assay of underivatized 5,5-diphenylhydantoin (Dilantin) in plasma extracts, Clin. Chetn., 17: 382-385, 1971.

1499. Sano, T., Suzuki, F., Sato, S., and Iida, Y., Mode of action of new anti-arrhythmic agents, Jap. Heart J., 9: 161-168, 1968.

1500. Sataline, L., Cardiac standstill simulating epileptic seizures, JAMA, 225: 747, 1973.

1501. Satoyoshi, E. and Yamada, K., Recurrent muscle spasms of central origin. A report of two cases, Arch. Neurol., 16: 254264.1967.

1502. Satoyoshi, E., Recurrent muscle spasms of central origin, Trans. Amer. Neurol. Assoc., 92: 153-157, 1967.

1503. Saunders, B. A. and Jenkins, L. C., Cardiac arrhythmias of central nervous system origin: possible mechanism and suppression, Canad. Anaesth. Soc. J., 20: 617-628, 1973.

1504. Savini, E. C., Poitevin, R. and Poitevin, J., New treatment of periodontolysis, Rev. Franc. Odontostomat., 19: 55-61, 1972.

1505. Schade, G. H. and Gofman, H., Abdominal epilepsy in childhood, Pediatrics, 25: 151-154, 1960.

1506. Scherlag, B. J. and Helfant, R. H., Effect of diphenylhydantoin on acetyl strophanthidin, Amer. Heart J., 81(4): 577-579, 1971.

1507. Scherlag, B. J., Helfant, R. H., Ricciutti, M. A., Damato, A. N., Dissociation of the effects of digitalis on myocardial potassium flux and contractility, Am. J. Physiology, 215: 1288-1291, 1968.

1508. Schick, D. and Scheuer, J., Current concepts of therapy with digitalis glycosides, Part II., Amer. Heart J., 87: 391-396, 1974.

1509. Schimmel, R. J., and Graham, D., Inhibition by diphenylhydantoin of the diabetogenic action of streptozotocin, Horm. Metab. Res., 6: 475-477, 1974.

1510. Schoor, W. P., Effect of anticonvulsant drugs on insecticide residues, Lancet, 520-521, 1970.

1511. Schreiber, M. M. and McGregor, J. G., Pseudolym phoma syndrome, Arch. Derm., 97: 297-300, 1968.

1512. Schulten, H. K., Etzrodi, H., du Mesnil de Rochernont, W., Chriske, H. W., Grosser, K. D. and Steinbruck, G., Clinical and electrophysiological observations in DPH therapy of arrhythmia, Verh. Deutsch Ges. Inn. Med., 77: 952-956, 1971.

1513. Schussler, G. C., Diazepam competes for thyroxine binding sites, Chem. Abstracts, 75: 74395C, 1971.

1514. Schussler, G. C., Similarity of diazepam to diphenylhy dantoin, JAMA, 218: 1832, 1971.

1515. Schwender, C. F., Antiarrhythrnic agents, Annual Reports in Medicinal Chemistry, 1970, 80-87, Cain, C. K., Ed., Academic Press, New York, 1971.

1516. Scientific Review Subpanel on Antiarrhythmia Agents, Quinidine-reserpine, Evaluations of Drug Interactions, American Pharmaceutical Association, Washington, D.C., 130-131, 1973.

1517. Scientific Review Subpanel on Anticonvulsants, Diphe. nylhydantoin-Isoniazid, Evaluations of Drug Interactions, American Pharmaceutical Association, Washington, D.C., 51-52, 1973.

1518. Scientific Review Subpanel on Anticonvulsants, Diphe nylhydantoin-phenobarbital, Evaluations of Drug Interactions, American Pharmaceutical Association, Washington, D.C., 54-56, 1973.

1519. Scientific Review Subpanel on Antidiabetic Agents, In sulin-diphenylhydantoin, Evaluation of Drug Interaction, American Pharmaceutical Association, Washington, D.C., 90-91, 1973.

1520. Scientific Review Subpanel on Anticonvulsants, Diphe nylhydantoin-rnethylphenidate, Evaluations of Drug Interactions, American Pharmaceutical Association, Washington, D.C. 53 54, 1973.

1521. Scientific Review Subpanel on Steroids, Dexarnetha sone-diphenylhydantoin, Evaluations of Drug Interactions, American Pharmaceutical Association, Washington, D.C., 32-34, 1973.

1522. Scientific Review Subpanel on Anticonvulsants, Anti convulsant therapy, Evaluations of Drug Interactions, American Pharmaceutical Association, Washington, D.C., 252-256, 1973.

1523. Scott, M., Peale, A. R., and Croissant, P. D., Intracranial midline anterior fossae ossifying fibroma invading orbits, paranasal sinuses, and right maxillary antrum, J. Neurosurg., 34: 827 831, 1971.

1524. Seeman, P., Chau-Wong, M., and Moyyen, S., The membrane binding of morphine, diphenylhydantoin, and tetrahydrocannabinol, Canad. J. Physiol. Pharmacol., 50: 1193-1200, 1972.

1525. Selye, H. and Szabo, S., Protection by various steroids against gold nephropathy, J. Eurap. Toxicol., 6: 512-516, 1972.

1526. Selye, H. and Tuchweber, B., Effect of various steroids upon the toxicity of bile acids, Int. Symp. Hepatotoxicity, 63, 1973.

1527. Selye, H., Szabo, S., and Kourounakis, P., Effect of var ious steroids and nonsteroidal microsomal enzyme inducers upon propoxyphene intoxication, Neuroendocrinology, 9: 316-3 1 9, 1972.

1528. Selye, H., Szabo, S. and Kourounakis, P., Protection against phenylisothicyanate by various steroids, phenobarbitone and diphenylhydantoin, J. Pharm. Phartnacol., 24: 333-334, 1972.

1529. Selye, H., Szabo, S., and Kourounakis, P., Protection by catatoxic steroids, phenobarbital and diphenylhydantoin against methaqualone intoxication, Steroids Lipids Res., 3: 156-159, 1972.

1530. Selye, H., Szabo, S., and Mecs, I., Protection by catatoxic steroids against the paralysis caused by combined treatment with thyroxine and methylphenidate, Neuropharmacology, II: 693-696, 1972.

1531. Selye, H., Hormones and resistance, J. Pharm. Sci., 60: 1-28, 1971.

1532. Selye, H., Prevention by catatoxic steroids of lithocholic acid-induced biliary concrements in the rat, Proc. Soc. Exp. Biol. Med., 141: 555-558, 1972.

1533. Selye, H., Protection by glucocorticoids against allopu rinol nephropathy, Acta Endocr., 69: 347-354, 1972. 1534. SCrrano, E. E., Roe, D. B., Hammer, R. H... and Wilder, B. J., Plasma diphenylhydantoin values after oral and intramus cular administration of diphenylhydantoin, Neurology, 23: 31 1 317, 1973.

1535. Shah, J. R., Vora, G., Karkhanis, A. V., and Talwalkar, C. V., The effect of diphenylhydantoin on ventilation tests in airway obstruction, Indian J. Chest. Dis., 12: 10-14, 1970.

1536. Shaisha, K. G., The function of newer antiarrhythmic drugs under special consideration of beta blocking adrenergic agents, Proc. Virchow Med Soc. (N.Y.). 27: 201-211, 1969.

1537. Shemano, I., Orzechowski, R., Gofdstein, S., and Beiler, M., Effects of 3,5-diethylhydantoin on resistance to asphyxia in rats, Toxic. AppL Pharmacol. 25: 250-258, 1973.

1538. Sher, S. P., Drug enzyme induction and drug interac tions: literature tabulation, Toxic. Appi. Pharmacol., IS: 780-834, 1971.

1539. Sherwin, A. L., Eisen, A. A. and Sokolowski, C. D., Anticonvulsant drugs in human epileptogenic brain, Presented at the annual meeting of the American Neurological Association and the Canadian Congress of Neurological Sciences, Montreal, 1973.

1540. Sherwin, I., Suppressant effects of diphenylhydantoin on the cortical epileptogenic focus, Neurology, 23: 274-281, 1973.

1541. Shibasaki, H. and Kuroiwa, Y., Painful tonic seizure in multiple sclerosis, Arch. Neurol., 30: 47-51, 1974.

1542. Shinohara, Y., Ventricular fibrillation threshold (VFRT) in experimental coronary occlusion: comparative studies on the effect of G-l-K solution and some new antiarrhythmic agents, Jap. Circ. J., 32: 1269-1281. 1968.

1543. Shoeman, D. W., Benjamin, D. M., and Azarnoff, D. L., The alteration of plasma proteins in uremia as reflected in the ability to bind diphenylhydantoin, Ann. N. Y. Acad. Sci., 226: 127 130, 1973.

1544. Shoeman, D. W., Kauffman, R. E., Azarnoff, D. L., and Boulos, B. M., Placental transfer of diphenylhydantoin as deter mined at constant drug concentrations in the maternal blood, Pharmacologist, 13: 195, 1971.

1545. Shoeman, D. W., Kauffman, R. E., Azarnoff, D. L., and Boulos, B. M., Placental transfer of diphenylhydantoin in the goat, Biochem. Pharmacol., 21: 1237-1244, 1972.

1546. Sholiton, L. J., Werk, E. E. and MacGee, J., The effect of diphenylhydantoin in vitro on the formation of the polar metabolites of testosterone by rat liver, Acia Endocr., 62: 360-366, 1969. 

1547. Siegel, G. H. and Goodwin, B. B., Sodium-potassiumactivated adenosine triphosphatase of brain microsomes: modification of sodium inhibition by diphenylhydantoins, J. Clin. Invest., 51: 1161-1169, 1972.

1548. Siegel, G. J. and Goodwin, B. B., Effects of 5,5-diphenlhydantoin (DPH) and 5-p-hydroxyphenyl-5-phenylhydantoin (H PPH) on brain Na-K-ATPase, Neurology, 21: 417, 1971.

1549. Sigwaid, J., Raverdy, P., Fardeau, M., Gremy, F., Mace de Lepinay, A., Bouttier, D., and Danic, Mme., Pseudomyotonia, Rev. Neurol., II 5: 1003-1014, 1966.

1550. Simon, G. E.,Jatlow, P. I., Seligson, H. T., and Seligson, D., Measurement of 5,5-diphenylhydantoin in blood using thin layer chromatography, Epilepsy Abstracts, 4: 136, 1971.

1551. Simopoulos, A. M., Pinto, A., Uhlenhuth, E. H., McGee, J. J., and DeRosa, E. R., Diphenylhydantoin (DPH) effectiveness in the treatment of chronic schizophrenics, Arch. Gen. Psychiat., 30: 106-112, 1974.

1552. Simpson, J. F., Use of diphenylhydantoin, Ann. Intem. Mtd., 78: 305-306, 1973.

1553. Singh, B. N. and Hauswirth, O., Comparative mechanisms of action of antiarrhythmic drugs, Amer. Heart J., 87: 367382, 1974.

1554. Singh, B. N. and Vaughan Williams, E. M., Effect of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle, Circ. Res., 29: 286-295, 1971.

1555. Singh, B. N., Explanation for the discrepancy in reported cardiac electrophysiological actions of diphenylhydantoin and lignocaine, Brit. J. Pharmarcol., 41: 385-386, 1971.

1556. Singh, H  ‘P., Hebert, M. A., and Gualt, M. H., Effect of some drugs on clinical laboratory values as determined by technicon SMA 12/60, Clin. Chem., 18: 137-144, 1972.

1557. Singh, N., Sinha, J. N., Rastogi, S. K., Dua, P. R., and Kohli, R. P., An experimental investigation on the antiarrhythmic activity of antiepileptic agents, Jap. J. Pharmacol. 21: 755-761, 1971.

1558. Sisca, T. S., An unusual dual hypersensitivity reaction induced by diphenylhydantoin, Amer. J. Hosp. Pharm., 30: 446449, 1973.

1559. Skrotsky, Y. A., Complications due to antiepiteptic therapy in children and adolescents, Epilepsy Abstracts, 7: 138-139, 1974.

1560. Slosberg, P. S., Medical therapy for the cerebrovascular insufficiencies; eight years’ experience, Mt. Sinai Med. J., 37: 692-698, 1970.

1561. Smith, J. S., Brierley, H. and Brandon, S., Akinetic mutisyn with recovery after repeated carbon monoxide poisoning, Psychol. Med., 1: 172-177, 1971.

1562. Smith, T. W. and Haber, E., Digitalis, New Eng. J. Mod., 289: 1125-1129, 1973.

1563. Smith, T. W., Digitalis glycosides, New Eng J. Med., 288: 942-946, 1973.

1564. Smith, W. L. and Lowrey, J. B., The effects of diphenylhydantoin on cognitive functions in man, Drugs, Development, and Cerebral Function, Smith, W. L., Ed., Charles C Thomas, 344-351, 1972.

1565. Smith, W. L. and Lowrey, J. B., Effects of diphenylhydantoin on mental abilities in the elderly, J. Amer. Geriat. Soc., 23: 207-211, 1975.

1566. Snider, R. S. and del Cerro, M., Diphenylhydantoin, proliferating membranes in cerebellum resulting from intoxication, Antiepileptic Drugs, 237-245, Woodbury, D. M., Penry, J. K., and Schmidt, R. P. Eds., Raven Press, New York, 1972.

1567. Sohn, R. S. and Ferrendelli, J. A., Inhibition of Ca+ + uptake in rat brain synaptosomes by diphenylhydantoin, Neurology, 23: 444, 1973.

1568. Solomon, G. E., Hilgartner, M. W., and Kutt, H., Coadulation defects caused by diphenylhydantoin, Neurology, 22: 1165-1171, 1972.

1569. Solomon, P. and Kleeman, S. T., Medical aspects of violence, Calif. Med., 114: 19-24, 1971.

1570. Solow, E. B. and Green, J. B., The simultaneous determination of multiple anticonvulsant drug levels by gas-liquid chromatography, Neurology, 22: 540-550, 1972.

1571. Solow, E. B., Metaxas, J. M. and Summers, T. R., Antiepileptic drugs. A current assessment of simultaneous determination of multiple drug therapy by gas liquid chromatography on column methylation, J. Chromatographic Sci., 12: 256-260, 1974.

1572. Sorrell, T. C., Forbes, 1. J., Burness, F. R., and Rischbieth, R. H. C., Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin), Lancet, 1233-1235, 1971.

1573. Sotaniemi, E. A., Arvela, P., Hakkarainen, H. K., and Huhti, E., The clinical significance of microsomal enzyme induction in the therapy of epileptic patients, Ann. Clin. Res., 2: 223-227, 1970.

1574. Sotaniemi, E. A., Hakkarainen, H. K., Puranen, J. A. and Lahti, R. O., Radiologic bone changes and hypocalcemia with anticonvulsant therapy in epilepsy, Ann. Intern. Med., 77(3): 389-394, 1972.

1575. South, J., Teratogenic effect of anticonvulsants, Lancet, 2:1154,1972.

1576. Spector, R. G., Effects of fonnyl tetrahydrofolic acid and noradrenaline on the oxygen consumption ofrat brain synaptosorne-mitrochondirial preparations, Brit. J. Pharmacol., 44: 279-285, 1972.

1577. Spector, R. G., Influence of folic acid on excitable tissues, Nature New Biol., 240: 247-249, 1972.

1578. Spector, R. G., The influence of anticonvulsant drugs on formyl tetrahydrofolic acid stimulation of rat brain respiration in vitro, Epilepsy Abstracts, 6: 110, 1973.

1579. Speidel, B. D. and Meadow, S. R., Maternal epilepsy and abnormalities of the fetus and newborn, Lancet, 839-843, October, 1972.

1580. Sperelakis, N. and Henn, F. A., Effect of diphenylhydantoin on membrane potentials and Na-K-ATPase of cultured chick heart cells, Amer. J. Physiol., 218: 1224-1227, 1970.

1581. Spina, A., Fyridinolcarbamate in the therapy of hemicrania syndromes, Acia Neurol., 27: 610-617, 1972.

1582. Spray, G. H. and Burns, D. G., Folate deficiency and anticonvulsant drugs, Brit. Med. J., 2: 167-168, April, 1972.

1583. Stambaugh, J. E. and Tucker, D., Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia, Diabetes, 23: 679-683, 1974.

1584. Stamp, T. C. B., Effects of long-term anticonvulsant therapy on calcium and vitamin D metabolism, Proc. Roy. Soc. Med., 67: 64-68, 1974.

1585. Stamp, T. C. B., Round, J. M., Rowe, D. J. F., and Haddad, J. G., Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs, Brit. Med. J., 4: 9-12, 1972.

1586. Staples, R. E., Teratology, Antiepileptic Drugs, 55-62, Woodbury, D. M., Penry, J. K., and Schmidt, R. P. Eds., Raven Press, New York, 1972. (cf. Kuenssberg and Knox, Lancet, 198, 1913, Millar and Nevin, Lancet, 328, 1973 and Stenchever and Jarvis, Amer. J. Obstet. Gynee., 109: 961, 1971.)

1587. Starreveld-Zimmerman, A. A. E., Van Der Kolk, W. J., Meinardi, H., and Elshove, J., Are anticonvulsants teratogenic?, Lancet, 48-49, July, 1973.

1588. Staunton, C., Stein, A. A., and Moss, G., The cerebral etiology of the respiratory distress syndrome (RDS): universal response, with prevention by unilateral pulmonary denervation, Surg. Forum, 24: 1973.

1589. Stavchansky, S. A., Lubawy, W. C. and Kostenbauder, H. B., Increase of hexobarbital sleeping time and inhibition of drug metabolism by the major metabolite of DPH, Life Sci. 14: 1535-1539, 1974.

1590. Stazi, C. and Marasa, G., Arrhythmias due to digitalis and their treatment, Ann. Med. Nov. (Roma), 77: 51-80, 1972.

1591. Stein, A. A. and Moss, G., Cerebral etiology of the respiratory distress syndrome: diphenylhydantoin (DPH) prophylaxis, Surg. Forum, 24: 433-435, 1973.

1592. Stephens, J. H. and Shaffer, J. W., A controlled replication of the effectiveness of diphenylhydantoin in reducing irritability and anxiety in selected neurotic outpatients, J. Clin. Pharmacol., 13: 351-356, 1973.

1593. Stephens, J. H., Shaffer, J. W., and Browli, C. C., A controlled comparison of the effects of diphenyihydantain and placebo on mood and psychomotor functioning in normal volunteers, J. Clin. Pharmacol., 14: 543-551, 1974.

1594. Stern, L. Z., Gruener, R., and Amundsen, P., Diphenylhydantoin for steroid-induced muscle weakness, JAMA, 223: 1287-1288, 1973.

1595. Stevens, H., Nine neuropathics, Mod. Ann., 37: 89-97, 1968.

1596. Stevens, M. W. and Harbison, R. D., Placental transfer of diphenylhydantoin: effects of species, gestational age, and route of administration, Teratology, 9: 317-326, 1974.

1597. Stevenson, M. M. and Gilbert, E. F., Anticonvulsants and hemorrhagic diseases of the newborn infant, J. Pedial., 516, 1970.

1598. Stone, N., Klein, M. D., and Lown, B., Diphenylhydantoin in the prevention of recurring ventricular tachycardia, Circulation, 43: 420-427, 1971.

1599. Stowell, A., Physiologic mechanisms and treatment of histaminic or petrosal neuralgia, Headache, 9: 187-194, 1970.

1600. Strauss, H., Rahm, W. E., and Barrera, S. E., Studies on a group of children with psychiatric disorders. I. Electroencephalographic studies, Psychosom. Med., 2: 34-42, 1940.

1601. Strittmatter, W. J. and Sornjen, G. G., Depression of sustained evoked potentials and glial depolarization in the spinal cord by barbiturates and by diphenylhydantoin, Brain Res., 55: 333-342, 1973.

1602. Su, P. C. and Feldman, D. S., Motor nerve terminal and muscle membrane stabilization by diphenylhydantoin administration, Arch. Neurol., 28: 376-379, 1973.

1603. Swaiman, K. F. and Stright, P. L., The effects of anticonvulsants on in vitro protein synthesis in immature brain, Brain Res., 58: 515-518, 1973.

1604. Swann, W. P., Effects of Dilantin on the repair of gingival wounds, Indiana University School of Dentistry Thesis, 1966.

1605. Sweet, W. H. and Wepsic, J. G., Relation of fiber size in trigeminal posterior root to conduction of impulses for pain and touch; production of analgesia without anesthesia in the effective treatment of trigeminal neuralgia, Trans. Ainer. Neurol. Assoc., 95: 134-139, 1970.

1606. Tabachnick, M., Hao, Y. L., and Korcek, L., Effect of oleate, dipheny[hydantoin and beparin on the binding of 125 I-thyroxine to purified thyroxine-binding globulin, J. Clin. Endoer., 36: 392-394, 1973.

1607. Taitz, L. S., Mental retardation elevated alkaline phosphatase, convulsive disorder and thickening of calvarium, Epilepsy Abstracts, 6: 228, 1973. (cf. Kattan, Amer. J. Roenig en., 110: 102, 1970.)

1608. Tappaz, M. and Pacheco, H., Effects of convulsant and anticonvulsant drugs on uptake of 14,-C GABA by rat brain slices, J. Pharmacol. (Paris), 4: 295-306, 1973.

1609. Tashima, C. K. and De Los Santos, R., Lymphoma and anticonvulsive therapy, JAMA, 228: 286-287, 1974.

1610. Tassinari, C. A. and Fine, R. D., Paroxysmal choreoathetosis, Proc. Aust. Assoc. Neurot., 6: 71-75, 1969.

1611. Taylor, C. R., Double-blind crossover study of diphenylhydantoin in angina pectoris, Chest, 66: 422-427, 1974.

1612. Taylor, J. D., Krahn, P. M. and Higgins, T. N., Serum copper levels and diphenylhydantoin, Amer. J. Clin. Path., 61: 577-578, 1974.

1613. Tenser, R. B. and Corbett,      Myokymia and facial contraction in brain stem glioma, Arch. Neurol., 30: 425-427, 1974.

1614. Thompson, C. E., Diphenylhydantoin for myotonia congenital, New Eng. J. Med., 286: 893, 1972.

1615. Thurkow, I., Wesseling, H., and Meijer, D. K. F., Estirnation of phenytoin in body fluids in the presence of sulphonyl urea compounds, Clin. Chim. Acta, 37: 509-513, 1972.

1616. Thurlow, H. J. and Girvin, J. P., Use of anti-epileptic medication in treating “flashbacks” from hallucinogenic drugs, Canad. Med. Assoc. J., 105: 947-948, 1971.

1617. Tigelaar, R. E., Rapport, R. L., Inman, J. K., and Kupferberg, H. J., A radioimmunoassay for diphenylhydantoin, Epilepsy Abstracts, 6: 113, 1973.

1618. Tisman, G., Herbert, V., Go, L. T., and Brenner, L., In vitro demonstration of immunosuppression without bone marrow suppression by alcohol and bleomycin, Clin. Res., 19: 730, 1971.

1619. Tobin, T., Dirdjosudjono, S., and Baskin, S. I., Pharmacokinetics and distribution of diphenylhydantoin in kittens, Amer. J. Vet. Res., 34: 951-954, 1973.

1620. Tolman, K. G., Jubiz, W., DeLuca, H. F. and Freston, W., Rickets associated with anticonvulsant medications, Clin. Res., 20: 414, 1972.

1621. Toman, J. E. P. and Sabelli, H. C., Comparative neuronal mechanisms, Epilepsia, 10: 179-192, 1969.

1622. Torretti, J., Hendler, E., Weinstein, E., Longnecker, R. E., and Epstein, F. H., Functional significance of Na-K-ATPase in the kidney: effects of ouabain inhibition, Amer. J. Physiol., 222: 1398-1405, 1972.

1623. Tovi, D., The use of antifibrinolytic drugs to prevent early recurrent aneurysmal subarachnoid haemorrhage, Acta Neuvol. Scand., 49: 163-175, 1973.

1624. Treasure, T. and Toseland, P. A., Hyperglycaemia due to phenytoin toxicity, Arch. Dis. Child., 46: 563-564, 1971.

1625. Tuchweber, B., Szabo, S., Kovacs, K., and Garg, B. D., Hormonal and nonhormonal factors influencing pyrrolizidine alkaloid hepatotoxicity, Int. Symp. Hepatotoxicity, 89, 1973.

1626. Turner, W. J., Dilantin effect on emotionally disturbed children, Drugs and Cerebral Function, 99-102, Smith, W. L., Ed., Charles C Thomas, 1970.

1627. Tyler, F. H., West, C. D., Jubiz, W., and Meikle, A. W., Ditantin and metyrapone: a clinically significant example of enzyme induction, Trans. Amer. Clin. Climal. Assoc., 81: 213-219, 1970.

1628. Tyrer, J. H., Eadie, M. J., and Sutherland, J. M., Investigation of an outbreak of anticonvulsant intoxication, Proc. Aust. Assoc. Neurot., 7: 15-18, 1970.

1629. Tyrer, J. H., Eadic, M. J., and Hooper, W. D., Further observations on an outbreak of diphenylhydantoin intoxication, Proc. Aust. Assoc. Neural., 8: 37-41, 1971.

1630. Uhlenhuth, E. H., Stephens, J. H., Dim, B. H., and Covi, L., Diphenylhydantoin and phenobarbital in the relief of psychoneurotic symptoms: a controlled comparison, Psychopharmacologia (Berlin), 27: 67-84, 1972.

1631. Uono, M., Treatment of myotonic dystrophy, Naika, 25: 664-668, 1970.

1632. Vaisrub, S., Diphenylhydantoin and insulin-secreting tumors, JAMA, 223: 553-554, 1973.

1633. Vaisrub, S., Diphenylhydantoin and early diabetes, JAMA, 226: 191, 1973.

1634. Vajda, F. J. E., Prineas, R. J., and Lovell, R. R. H., Interaction between phenytoin and the benzodiazepines, Epilepsy Abstracts, 4: 263, 1971.

1635. Vajda, F. J. E., Prineas, R. J., Lovell, R. R. H., and Sloman, J. G., The possible effect of long-term high plasma levels of phenytoin on mortality after acute myocardial infarction, Europ. J. Clin. Pharmacol., 5: 138-144, 1973.

1636. van der Kleijn, E., Rijntjes, N. V. M., Guelen, P. J. M., and Wijffels, C. C. G., Systemic and brain distribution of diphenylhydantoin in the squirrel monkey, Antiepiteptic Drugs, 124, Woodbury, D. M., Penry, J. K., and Schmidt, R. P., Eds., Raven Press, New York, 1972.

1637. Van Der Velde, C. D., Toxicity of lithium carbonate in elderly patients, Am. J. Psychiat., 127: 1075-1077, 1971.

1638. van Dijk, L., Pharmacotherapy of cardiac arrhythmias in acute myocardial infarction, Folia Med. Neerl., 14: 225-236, 1971.

1639. Van Meter, J. C., Buckmaster, B. S., and Shelley, L. L., Concurrent assay of phenobarbital and diphenylhydantoin in plasma by vapor-phase chromatography, Clin. Chem., 16: 135138, 1970.

1640. Van Rees, H. and Noach, E. L., The intestinal absorption of diphenylhydantoin from a suspension in rats, Epilepsy Abstracts, 7: 197, 1974.

1641. Van Rees, H., DeWolff, F. A., Noach, E. L., The influence of diphenylhydantoin on intestinal glucose absorption in the rat, European J. Pharmacology, 28: 310-315, 1974.

1642. Van Rees, H., Woodbury, D. M. and Noach, E. L., Effects of ouabain and diphenylhydantoin on electrolyte and water shifts during intestinal absorption in the rat, Arch. Int. Pharmacodyn., 182: 437, 1969.

1643. Van Riezen, H. and Delver, A., The effect of a number of drugs with different pharmacological properties upon reserpine induced hypothermia in mice, Arzneimittelforschung., 21: 1562-1566, 1971.

1644. Vanasin, B., Bass, D. D., Mendeloff, A. I., and Schuster, M. M., Alteration of electrical and motor activity of human and dog rectum by diphenylhydantoin, Amer. J. Dig. Dis., 18: 403-410, 1973.

1645. Vander Ark, C. R. and Reynolds, E. W., Jr., Cellular basis and clinical evaluation of antiarrhythmic therapy, Med. Clin. N. Amer., 53: 1297-1308, 1969.

1646. Vaughan Williams, E. M., The development of new antidysrhythmic drugs, Schweiz. Med. Wschr., 103: 262-271, 1973.

1647. Vedso, S., Rud, C., and Place, J. F., Determination of phenytoin in serum in the presence of barbiturates sulthiame and ethosuximid by thin-layer chromatography, Scand. J. Clin. Lab. Invest., 23: 175-180, 1969.

1648. Verebel, K., Kutt, H., Sohn, Y. J., Levitt, B., and Raines, A., Uptake and distribution of diphenylthiohydantoin (DPTH), Europ. J. Pharmacol., 10: 106-110, 1970.

1649. Villareale, M., Gould, L. V., Wasserman, R. H., Barr, A., Chiroff, R. T., and Bergstrom, W. H., Diphenylhydantoin: effects on calcium metabolism in the chick, Science, 183: 671-673, 1974.

1650. Viukari, N. M. A. and Tammisto, P., Central effects of diphenylhydantoin (Dilantin) in epileptic oligophrenics during phenobarbital-primidone withdrawal, sodium bicarbonate, and ammonium chloride administration, Behav. Neuropsychiatr., 1: 1316, 1969.

1651. Viukari, N. M. A., Diphenylhydantoin as an anticonvulsant: evaluation of treatment in forty mentally subnormal epileptics, Epilepsy Abstracts, 3: 150, 1970.

1652. Vulliamy, D., Unwanted effects of anticonvulsant drugs, Dev. Med. Child. Neurol., 13: 107-109, 1971.

1653. Walker, W. J., Treatment of heart failure,JAMA, 228: 1276-1278, 1974.

1654. Wallace, J. E., Microdetermination of diphenylhydantoin in biological specimens by ultraviolet spectrophotometry, Anal. Chem., 40: 978-980, 1968.

1655. Wallace, J. E., Simultaneous spectrophotometric determination of diphenylhydantoin and phenobarbital in biologic specimens, Clin. Chem., 15: 323-330, 1969.

1656. Wallace, J. E., Spectrophotometric determination of diphenylhydantoin, J. Forensic Sci. Soc., 11: 552-559, 1966.

1657. Wallis, W. E. and Plum, F., Continuous fasciculations, myokymia and muscle contraction due to peripheral nerve disease, Trans. Assoc. Amer. Physicians, 82: 286-292, 1969.

1658. Wallis, W. E., Van Poznak, A., and Plum, F., Generalized muscular stiffness, fasciculations, and myokymia of peripheral nerve origin, Arch. Neurol., 22: 430-439, 1970.

1659. Walsh, G. O., Masiand, W., and Goldensohn, E. S., Relationship between paroxysmal atrial tachycardia and paroxysmal cerebral discharges, Bull. Los Angeles Neurol. Soc., 37: 28-35, 1972.

1660. Ware, E., The chemistry of the hydantoins, Chem. Rev., 46: 403-470, 1950.

1661. Watanabe, Y., A-V conduction disturbance: its pathophysiology and pharmacology, Singapore Med. J., 14(3): 249, 1973.

1662. Watson, E. L. and Woodbury, D. M., Effect of diphenylhydantoin on active sodium transport in frog skin, J. Pharmacol. Exp. Ther., 180: 767-776, 1972.

1663. Watson, E. L. and Woodbury, D. M., The effect of diphenylhydantoin and ouabain, alone and in combination, on the electrocardiogram and on cellular electrolytes of guinea-pig heart and skeletal muscle, Arch. Int. Pharmacodyn., 201: 389-399, 1973.

1664. Watson, E. L. and Woodbury, D. M., Effects of diphenylhydantoin on electrolyte transport in various tissues, Chemical Modulation of Brain Function, 187-198, Sabelli, H. C., Ed., Raven Press, New York, 1973.

1665. Watson, J. D. and Spellacy, W. N., Neonatal effects of maternal treatment with the anticonvulsant drug diphenylhydantoin, Obstet. Gynee., 37: 881-885, 1971.

1666. Watson, M., Gabica, J., and Benson, W. W., Serum organochlorine pesticides in mentally retarded patients on differing drug regimens, Clin. Pharmacol. Ther., 13: 186-192, 1972.

1667. Watson, P., Brainwave to save life, London Times, 1973.

1668. Wax, S. D., Webb, W. R., and Ecker, R. R., Myocardium stabilization by diphenylhydantoin, Surg. Forum, 20: 164-166, 1969.

1669. Weber-Eggenberger, S. and Kaufmann, G., Studies on absorption, elimination and antiarrhythmic serum concentrations of diphenylhydantoin (antisacer) in digitalized heart patients, Z. Kreislaufforsch., 60: 420-432, 1971.

1670. Weckman, N. and Lehtovaara, R., Serum and cerebrospinal fluid folate values in epileptics on anticonvulsant treat ment, Scand. J. Clin. Lab. Invest., Supp. 10 1, 120-121, 1968.

1671. Weckman, N. and Lehtovaara, R., Folic acid and anticonvulsants, Lancet, 1: 207-208, 1969.

1672. Weinreich, D. and Clark, L. D., Anticonvulsant drugs and self-stimulation rates in rats, Arch. Int. Pharmaeodyn., 185: 269-273, 1970.

1673. Weisse, A. B., Moschos, C. B., Passannante, A. J., and Regan, T. J., Comparative effectiveness of procaine amide, lidocaine, and diphenylhydantoin in treating ventricular arrhythmias during acute myocardial infarction, Circulation, 38: VI205, 1968.

1674. Weiss, C. F., Yaffe, S. J., Cann, H. M., Gold, A. P., Kenny, F. M., Riley, H. D., Schafer, I., Stern, L., and Shirkey, H. C., An evaluation of the pharmacologic approaches to learning impediments, Pediatrics, 46: 142-144, 1970.

1675. Weisse, A. B., Moschos, C. B., Passannante, A. J., Khan, M. I., and Regan, T. J., Relative effectiveness of three antiarrhythmic agents in the treatment of ventricular arrhythmias in experimental acute myocardial ischemia, Amer. Heart J., 81: 503510, 1971.

1676. Welch, L. K., Appenzeller, O., and Bicknell, J. M., Peripheral neuropathy with myokymia, sustained muscular contraction, and continuous motor unit activity, Neurology, 22: 161169, 1972.

1677. Wepsic, J. G., Tic douloureux: etiology, refined treatment, New Eng. J. Mod., 288: 680-681, 1973.

1678. Werk, E. E., Choi, Y., Sholiton, L., Olinger, C., and Haque, N., Interference in the effect of dexamethasone by diphenylhydantoin, New Eng. J. Med., 281: 32-34, 1969.

1679. Werk, E. E., Thrasher, K., Sholiton, L. J., Olinger, C., and Choi, Y., Cortisol production in epileptic patients treated with diphenylhydantoin, Clin. Pharmacol. Ther., 12: 698-703, 1971.

1680. Wesseling, H. and Thurkow, I., Effect of sulphonyluteas (tolazamide, tolbutamide and chlorpropamide) on the metabolism of diphenylhydantoin in the rat, Biochem. Pharmacol., 22: 3033-3040, 1973.

1681. Westmoreland, B. and Bass, N. H., Chronic diphenylhydantoin intoxication in the albino rat during pregnancy, Neurology, 20: 411, 1970.

1682. Whelton, A., Snyder, D. S., and Walker, W. G., Acute toxic drug ingestions at the Johns Hopkins Hospital 1963 through 1970, Johns Hopkins Med. J., 132: 157-167, 1973.

1683. White, C. W., Jr., Megirian, R., and Swiss, E. D., The effects of diphenylhydantoin sodium, glucose and 0-diethylaniinoethyl diphenylpropylacetate hydrochloride on cyclopropane-epinephrine arrhythrnias in the dog, Circ. Res., 3: 290-292, 1955.

1684. Wilder, B. J., Buchanan, R. A., and Serrano, E. E., Correlation of acute diphenylhydantoin intoxication with plasma levels and metabolite excretion, Neurology, 23: 1329-1332, 1973.

1685. Wilder, B. J., Serrano, E. E. and Ramsay, R. E., Plasma diphenylhydantoin levels after loading and maintenance doses, Clin. Pharmatol. Ther., 14: 797-801, 1973.

1686. Wilder, B. J., Streiff, R. R., and Hammer, R. H., Diphenylhydantoin, absorption, distribution, and excretion: clinical studies, Antiepileptic Drugs, 137-148, Woodbury, D. M., Penry, J. K., and Schmidt, R. P., Eds., Raven Press, New York, 1972.

1687. Wilensky, A. J. and Lowden, J. A., Interaction of diphenylhydantoin 414C with subcellular fractions of rat brain, Epilepsy Abstracts, 5: 194, 1972.

1688. Wilensky, A. J. and Lowden, J. A., The inhibitory effect of diphenylhydantoin on microsomal ATPases, Life Sci., II: 319327, 1972.

1689. Wilensky, A. J. and Lowden, J. A., Inadequate serum levels after intramuscular administration of diphenylhydantoin, Neurology, 23: 318-324, 1973.

1690. Wilkinson, H. A., Epileptic pain-an uncommon manifestation with localizing value, Neurology, 23: 518-520, 1973.

1691. Wilson, J. T. and Wilkinson, G. R., Delivery of anticonvulsant drug therapy in epileptic patients assessed by plasma level analyses, Neurology, 24: 614-623, 1974.

1692. Winter, B., Bilateral carotid body resection for asthma and emphysema, Int. Surg., 57: 458-466, 1972.

1693. Wolff, J., Standaert, M. E., and Rall, J. E., Thyroxine displacement from serum proteins and depression of serum protein-bound iodine by certain drugs, J. Clin. Invest., 40: 13731377, 1961.

1694. Wood, R. A., Sinoatrial arrest: an interaction between phenytoin and lignocaine, Brit. Med. J., 1: 645, 1971.

1695. Woodbury, D. M. and Kemp, J. W., Some possible mechanisms of action of anti-epileptic drugs, Pharmakopsychiatr., 3: 201-226, 1970.

1696. Woodbury, D. M. and Kemp, J. W., Pharmacology and mechanisms of action of diphenylhydantoin, Psychiat. Neurol. Neurochir., 74: 91-115, 1971.

1697. Woodbury, D. M. and Swinyard, E. A., Diphenylhydantoin, absorption, distribution, and excretion, Antiepileptic Drugs, 113-123, Woodbury, D. M., Penry, J. K., and Schmidt, R. P., Ed.%., Raven Press, New York, 1972.

1698. Woodbury, D. M., Koch, A., and Vernadakis, A., Relation between excitability and metabolism in brain as elucidated by anticonvulsant drugs, Neurology, 8: 113-116, 1958.

1699. Woodbury, D. M., Mechanisms of action of anticonvulsants, Epilepsy Abstracts, 3: 248, 1970.

1700. Woodbury, D. M., Penry, J. K. and Schmidt, R. P., Eds., Antiepileptic Drugs, Raven Press, New York, 1972.

1701. Yalaz, K. and Baytok, V., Mirror movement, Turk. Pediat., 12: 85-88, 1970.

1702. Yanagihara, T. and Hamberger, A., Effect of diphenylhydantoin on protein metabolism in the central nervous system-study of subcellular fractions, Exp. Neurol, 31: 87-99, 1971.

1703. Yanagihara, T. and Hamberger, A., Effect of diphe. nylhydantoin on protein metabolism in neuron and neuroglial fractions of central nervous tissue, Exp. Neurol, 32: 152-162, 1971.

1704. Yanagihara, T., Distribution of diphenylhydantoin in the neuronal and glial fractions, Antiepileptic Drugs, 125-126, Woodbury, D. M., Penry, J. K., and Schmidt, R. P., Eds., Raven Press, New York, 1972.

1705. Yang, C. P., Persistent ventricular tachycardia. The use of diphenylhydantoin, J. Kansas Med. Soc., 74: 418-421, 1973.

1706. Yaryura-Tobias, J. A. and Nezirogiu, F., Violent behaviour, brain dysrhythmia and glucose dysfunction: a new syndrome, Am. J. Psychiat., 130: 825, 1973.

1707. Yasky, J., Moretti, O., Caroselia, C., Phenytoin treatment of cardiac arrhythmias induced by digitalis, Revista Argentina de Cardiologia, 41: 53-61, 1973.

1708. Yoshida, T. and Arakawa, T., Serum histidine clearance in children with diphenythydantain administration, Tohoku J. Exp. Med., 112: 257-259, 1974.

1709. Yoshimasu, F., Kurland, L. T., and Elveback, L. R., Tic clouloureux in Rochester, Minnesota, 1945-1969, Neurology, 22: 952-956, 1972.

1710. Zanini, S. and Rossi, R., Ventricular parasystole: effective treatment with diphenylhydantoin, G. Ital. Cardiol., 2: 575578, 1972.

1711. Zeft, H. J., Rembert, J. C., Curry, C. L., and Greenfield, C., Effects of diphenylhydantoin on coronary and systemic haemodynamics in awake dogs, Cardiovasc. Res., 7: 331-335, 1973.

1712. Zeft, H. J., Whalen, R. E., Morris, Jr., Rummo, N. J., and Mclntoch, H. D., Prophylaxis versus treatment of acetvlstrophanthidin intoxication. Amer. Heart J., 77: 237-245, 1969.

1713. Affrime, M. and Reidenberg, M. M., The protein binding of some drugs in plasma from patients with alcoholic liver disease, Europ. J. Clin. Pharmacol., 8: 267-9, 1975.

1714. Agapova, E. N. and Mikhalev, I. D., Effectiveness of the use of diphenine in insuloma, Ter. Arkh., 49(9): 124-5, 1977.

1715. Agnew, D. C. and Goldberg, V. D., A brief trial of phenytoin therapy for thalamic pain, Bulletin Los Angeles Neurol. Soc., 41(l): 9-12, 1976.

1716. Aickin, C. C., Deisz, R. A. and Lux, H. D., The effect of diphenylhydantoin and picrotoxin on post-synaptic inhibition, J. Physiol., 284: 125-6, 1978.

1717. Aldrete, J. A. and Franatovic, Y., Postponement of operations-its prevention in patients found to be mildly hypertensive, Arch. Surg., 115: 1204-6, 1980.

1718. Aldrete, J. A., Romo Salas, F., Jankovsky, L. and Franatovic, Y., Effect of pretreatment with thiopental and phenytoin on postischemic brain damage in rabbits, Critical Care Medicine, 7(10): 466-70, 1979.

1719. Aldrete, J. A., Romo-Salas, F., Mazzia, V. D. B. and Tan, S., Diphenylhydantoin for reversal of neurological injury after cardiac arrest, Rev. Bias. Anest., 30(4): 263-7, 1980.

1720. Ali, 1. 1. and I)utta, S., Distribution of C14-diphenylhydantoin (DPH) in Creation to its antidysrhythmic effect in dogs, Fed. Proe. 36: 1012, 1977.

1721. Allen, M. A., Wrenn, J. M., Putney, J. W. and Borzelieca, J. F., A study of the mechanism of transport of diphenylhydantoin in the rat submakillary gland in vitro, J. Pharmacol. Exp. Ther., 197(2): 408-13, 1976.

1722. Anderson, R. J. and Raines, A., Suppression of decerebrate rigidity by phenytoin and chlorpromazine, Neurol., 26: 858-62,1976.

1723. Appenzeller, O., Feldman, R. G. and Friedman, A. P., Migraine, headache, and related conditions, Arch. Neurol.., 36: 784-805,1979.

1724. Apton, R., Dilantin and its relation to caries incidence, Dent. Hyg., 51: 349-51, 1977.

1725. Arnaout, M. A. and Salti, I., Phenytoin in benign insulinoma, Lancet, 861, 1976.

1726. Arnsdorf, M. F. and Meblman, D. J., Observations on the effects of selected antiarrhythmic drugs on mammalian car. diac Purkinje fibers with two levels of steady-state potential: Influences of lidocaine, phenytoin, propranolol, disopyramide and procainamide on repolarization, action potential shape and conduction, J. Pharmacol. Exp. Ther., 207(3): 983-91, 1978.

1727. Artru, A. A. and Michenfelder, J. D., Cerebral potagsium release reduced by diphenylhydantoin: mechanism of cerebral protection, Ann. Neurot., 6(2): 151, 1979.

1728. Artru, A. A. and Michenfelder, J. D., Cerebral protective, metabolic, and vascular effects of phenytoin, Stroke, 11(4): 377-82, 1980.

1729. Asboe-Hansen, G., Treatment of generalized scleroderma: updated results, Acta Derm. Venereol., 59(5): 465-7, 1979.

1730. Ayala, G. F. and Johnston, D., Phenytoin: electrophysiological studies in simple neuronal systems, Antiepileptic Drugs: Mechanisms of Action, 339-5 1, Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Raven Press, New York, 1980.

1731. Ayala, G. F. and Johnston, D., The influences of phenytoin on the fundamental electrical properties of simple neural systems, Epilepsia, 18(3): 299-307, 1977.

1732. Ayala, G. F., Johnson, D., Lin, S., and Dichter, H. N., The mechanism of action of diphenylhydantoin on invertebrate neurons: II. Effects on synaptic mechanisms, Brain Res., 121: 259-70, 1977.

1733. Ayala, G. F., Lin, S. and Johnston, D., The mechanism of action of diphenylhydantoin on invertebrate neurons: 1. Effects on basic membrane properties, Brain Res., 121: 245-58, 1977.

1734. Baselt, R. C. and Cravey, R. H., A compendium of therapeutic and toxic concentrations of toxicologically significant drugs in human biofluids, J. Anal. Toxicol., 1: 81-103, 1977.

1735. Baskin, S. I., Leibman, A. J., DeWitt, W. S., Orr, P. L., Tarzy, N. T., Levy, P., Krusz, J. C., Dhopesh, V. P. and Schraeder, P. L., Mechanism of the anticonvulsant action of phenytoin: regulation of central nervous system taurine levels, Neurology, 28(4): 331-2, 1978.

1736. Baskin, S. 1. and Melrose, B. L., The effect of diphenylhydantoin on the formation and dissociation of the cardiac glycoside-(Na’ + K’)-ATPase complex, Clin. Res., 23: 172A, April 1975.

1737. Baratz, R. and Mesulam, M. M., Adult-onset stuttering treated with anticonvulsants, Arch. Neurol., 38: 132, 1981.

1738. Bauer, E. A., Cooper, T. W., Tucker, D. R. and Esterly, N. B., Phenytoin therapy of recessive dystrophic epidermolysis bullosa: clinical trial and proposed mechanism of action on collagenase, New Eng. J. Med., 303(14): 776-81, 1980.

1739. Bayer, R., Kaufmann, R. and Gudjons, M., The effects of diphenylhydantoin on mechanical and electrical properties of isolated cat myocardium, Naunyn-Schmied. Arch. Phammcol., 298: 273-82,1977.

1740. Bechtel, P., Delafin, C. and Bechtel, Y., Induction of hepatic cytochrome P-450 and b5 in mice by phenytoin during chronic hypoxia, C. R. Soc. Biol. (Paris), 170(2): 325-30, 1976.

1741. Beckner, T. F. and ldsvoog, P., Drug use and distribution in a pain rehabilitation center, Am. J. Hosp. Pharm., 32: 285-9,1975.

1742. Benowitz, N. L., Rosenberg, J. and Becker, C. E., Cardiopulmonary catastrophes in drug-overdosed patients, Med. Clin. North Am., 63(10): 267-96, 1979.

1743. Berger, M. and Berchtold, P., Side effects of antiepileptic agents, Dtsch. Med. Wschr., 100: 2552, 1975.

1744. Berger, M., Berchtold, P., Cuppers, H. J., Wiegelmann, W., Drost, 14., Sailer, R., Borchard, F. and Zimmermann, H., Suppressibility of serum insulin in patients with insulinoma by somatostatin, diazoxide and diphenylhydantoin, Presented at 4th International Danube Symposium on Diabetes Mellitus, Dubrovnik, 1975.

1745. Bianchi, C. P., Cell calcium and malignant hyperthermia, International Symposium an Malignant Hyperthermia, 147-51, Gordon, R. A., Britt, B. A. and Kalow, W., Eds., Charles C Thomas, Illinois, 1973.

1746. Bianchi, C., Beani, L. and Bertelli, A., Effects of some antiepileptic drugs on brain acetylcholine, Epilepsy Abstracts, 8(9): 231, 1975.

1747. Biberdorf, R. 1. and Spurbeck, G. H., Phenytoin in IV fluids: results endorsed, Drug Intell. Clin. Pharm., 12: 300-1, 1978.

1748. Bigger, J. T., Antiarrhythmic drugs in ischemic heart disease, Hosp. Pract., 7: 69-80, 1972. 1749. Bigger, J. T., Heissenbuttel, R. H. and Lovejoy, W. P., .Management of cardiac problems in the intensive care unit, Med. Clin. N. Am., 55: 1183-1205, 1971.

1750. Bihler, 1. and Sawh, P. C., Effects of Diphenylhydantoin on the transport of Na+ and K+ and the regulation of sugar transport in muscle in vitro, Biochim. Biophys. Acta, 249: 240-51, 1971.

1751. Binnion, P. F. and DasGupta, R. Tritiated digoxin metabolism after prior treatment with propranalof or diphenylhydantoin sodium, Int. J. Clin. Pharmacol., 12: 96-101, 1975.

1752. Biryukov, V. B., The treatment of patients with different forms of myotonia with diphenine and novocainamide, Zh. Neurepatol, Psikhiatr., 76: 1333-5, 1976.

1753. Boller, F., Wright, D. G., Cavalieri, R. and Mitsumoto, H., Paroxysmal “nightmares,” Neurology, 25: 1026-28, 1975.

1754. Boon, W. H., Benign myoclonus in infants and children, J. Singapore Paediat. Soc., 20(2): 60-8, 1978.

1755. Bowdle, T. A., Neal, G. D., Levy, R. H. and Heimbach, D. M., Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients, J. Pharinacol. Exp. Ther., 213(l): 97-9, 1980.

1756. Bricaire, H., Luton, J. P., Wechsler, B., Messing, B. and Halaby, G., Inappropriate secretion of insulin by an islet cell adenoma. Trial treatment with diphenylhydantoin, Ann. Med. Intern., 127(5): 403-7, 1976.

1757. British Medical journal, Editor, Treatment of tinnitus, Br. Mod. J., 1445-6, 1979.

1758. Broser, F., Ditzen, G. and Friedrich, K., Complementary electro-physiological findings in a case of neuromytonia, Nervenarzt, 46: 100-4, 1975.

1759. Buda, F. B. and Joyce, R. P., Successful treatment of atypical migraine of childhood with anticonvulsants, Mil. Med., 144(8): 521-3, 1979.

1760. Bustamante, L., Lueders, H., Pippenger, C. and Goldensohn, E. S., The effects of phenytoin on the penicillininduced spike focus, Electromcephalogr. Clin. Neurophysiol., 48: 90-7, 1980.

1761. Caillard, C., Menu, A., Plotkine, M. and Rossignol, P., Do anticonvulsant drugs exert protective effect against hypoxia?, Life Sci., 16: 1607-12, 1975.

1762. Callaghan, N., Feely, M., O’Callaghan, M., Duggan, B., McGarry, J., Cramer, B., Wheelan, J. and Seldrup, J., The effects of toxic and non-toxic serum phenytoin levels on carbohydrate tolerance and insulin levels, Acta Neurol. Scand., 56: 563-71, 1977.

1763. Caplan, L. R., Weiner, H., Weintraub, R. M. and Austen, W. G., “Migrainous” neurologic dysfunction in patients with prosthetic cardiac valves, Headache, 16: 218-21, 1976.

1764. Carney, J. M., Rosecrans, J. A. and Vasko, M. R., Barbitone-induced tolerance to the effects of sedative hypnotics and related compounds on operant behavior in the rat, Br. J. Pharmac., 65: 183-92, 1979.

1765. Carson, 1. W., Lyons, S. M. and Shanks, R. G., Antiarrhythmic drugs, Br. J. Anaesth., 51: 659-70, 1979.

1766. Celis, G. R., Kula, R. W., Somasundaram, M., Sher, H. and Schutta, H. S., Myokymia of segmental spinal cord origin, Ann. Neurot., 8(l): 95, 1980.

1767. Chadda, V. S. and Mathur, M. S., Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy, J. Assoc. Phys. Ind., 26: 403-6, 1978.

1768. Chai, C. Y., Lee, T. M. and Wang, S. C., Effects of diphenylhydantoin on cardiac arrhythmias induced by carotid occlusion in the cat, Arch. Int. Pharmacodyn., 219: 180-92,1976.

1769. Chalfie, M. and Perlman, R. L., Inhibition of catecholamine synthesis and tyrosine 3-monooxygenase activation in pheochromocytoma cells by diphenylhydantoin, Neurochem., 29: 757-9, 1977.

1770. Chapa-Alvarez, J. R., Francisco-Mendiola, J., EspejoPlaseencia, 1. and Rodriguez-Noriega, E., Results obtained in the treatment of burns with sodium diphenythydantoin, Personal Communication, 1981.

1771. Chapman, J. H., Schrank, J. P. and Crampton, R. S., Idiopathic ventricular tachycardia-an intracardiac electrical hemodynamic and angiographic assessment of six patients, Am. Med., 59: 470-80, 1975.

1772. Cisson, C. M., Entrikin, R. K. and Wilson, B. W., Actions of phenytoin on acetylcholinesterase (ACHE), creatine kinase (CK) and protein of cultured chick embryo muscle, Fed. Proc., 36: 498, March, 1977.

1773. Clemmesen, J., Incidence of neoplasms in a population on anti-convulsant drugs, Anti-convulsant Drugs and Enzyme Induction, Study Group 9 of the Institute for Research into Mental and MultiplHandicap, 123-30, Richens, A. and Woodford, F. P., Eds., Associated Scientific Publication, Amsterdam, 1976.

1774. Cloyd, J. C., Bosch, D. E. and Sawchuk, R. J., Concentration-time profile of phenytoin after admixture with small volumes of intravenous fluids, Am. J. Hosp. Pharm., 35: 45-8, 1978.

1775. Cobbs, B. W. and Kings, S. B., Ventricular buckling: A factor in the abnormal venti-iculogran and peculiar hemodynamics associated with mitral valve prolapse, Am. Heart J., 93(6): 741-58,1977.

1776. Cochran, P. T., Linnebur, A. C., Wright, W. and Matsumoto, S., Electrophysiologic studies in patients with long Q-T syndrome, Clin. Res., 25(2): 88A, Feb. 1977.

1777. Cohan, S. L., Anderson, R. J. and Raines, A., Dipbenylhydantoin and chlorpromazine in the treatment of spasticity, Neurology, 367, April, 1976.

1778. Cohan, S. L., Raines, A., Panagakos, J. and Armitage, P., Phenytoin and chlorpromazine in the treatment of spasticity, Arch. Neurol., 37: 360-4, 1980.

1779. Cohen, L. S., Diphenylhydantoin sodium (Dilantin), Current Cardiovascular Topics, Vol. I., Drugs in Cardiology, Part 1, 49-79, Donoso, E., Ed., Stratton Intercontinental Medical Book Corp., New York, 1975.

1780. Connors, B. W., Pentobarbital and diphenylhydantoin effects on the excitability and GABA sensitivity of rat dorsal root ganglion cells, Society for Neuroscience, 9th Annual Meeting, Nov. 2-6,1979.

1781. Cookson, S. L. and Mann, J. D., Reversal and prevention of acute morphine induced catalepsy by phenytoin in naive rats, Neurosci. Absir., 4: 488, 1978.

1782. Cordone, G., lester, A., Venzano, V. and Minetti, C., A case of Thomsen’s disease associated with hypoparathyroidism, Minerva Pedialtica., 30: 1629-34, 1979.

1783. Corr,, P. B. and Gillis, R. A., Beneficial cardiac rhythm effects produced by diphenylhydantoin in experimental myocardial infarction, Fed. Proc., 35: 222, 1976.

1784. Cotler, H. M. and Christensen, H. D., Tissue distribution of diphenylhydantoin, Fed. Proc., 35: 664, 1976.

1785. Counsell, R. E., Ranada, V. V., Kline, W., Hong, B. H. and Buswink, A. A., Potential organ or tumor imaging agents XV: radioiodinated phenytoin derivatives, J. of Pharmac. Sci., 65(2): 285-7, 1976.

1786. Crampton, R. S., Another link between the left stellate ganglion and the long Q-T syndrome, Am. Heart J., 96(i): 130-2,1978.

1787. Cudworth, A. G. and Barber, H. E., The effect of bydrocortisone phosphate, methylprednisolone and phenytoin on pancreatic insulin release and hepatic glutathione-insulin transhydrogenase activity in the rat, Europ. J. Pharmacol., 31: 23-8, 1975.

1788. Cullen, J. P., Aldrete, J. A., jankovsky, L. and RomoSalas, F., Protective action of phenytoin in cerebral ischemia, Anesth. Anaig., 58: 165-9, 1979.

1789. Dadkar, M. K., Gupte, R. D. and Dohadwalia, A. M., Effect of diphenylhydantoin on blood pressure of spontaneously hypertensive rats, Med. Biol., 57: 398-401, 1979.

1790. Dalessio, D. J., Medical treatment of trigeminal neuralgia, Clin. Neurosurg., 24: 579-83, 1976.

1791. Das, D., Ayromlooi, J., Tobias, M., Desiderio, D. and Steinberg, H., Effect of Dilantin (D) on hypoxic fetal rabbit lung, Pediatr. Res., 14: 640, 1980.

1792. Data, J. L., Wilkinson, G. R. and Nies, A. S., Interaction of quinidine with anticonvulsant drugs, New Eng. J. Med., 294(13): 699-702, 1976.

1793. Dawson, G. W., Brown, H. W. and Clark, B. G., Serum phenytoin after ethosuximide, Neurology, 4(6): 583-4, 1978.

1794. Deisz, R. A. and Lux, H. D., Diphenylhydantoin prolongs post-synaptic inhibition and iontophoretic GABA action in the crayfish stretch receptor, Neuroscience Letters, 5: 199-203, 1977.

1795. Deisz, R. A. and Lux, H. D., Postsynaptic inhibition of the crayfish stretch receptor: prolongation by diphenylhydantoin, Pflugers Arch. Ges. Physiol., Suppi. 368: R33, 1977.

1796. Dekeban, A. S. and Lehman, E. J. B., Effects of different dosages of anticonvulsant drugs on mental performance in patients with chronic epilepsy, Acta Neurol. Scand., 52: 319-30, 1975.

1797. de la Torre, R., Murgia-Suarez, J. J. and Aldrete, J. A., Comparison of phenytoin and conventional drug therapy in the treatment of mild hypertension, Clin. Ther., 3(4): 117-24, 1980.

1798. Delgado-Escueta, A. V. and Horan, M. P., Phenytoin: biochemical membrane studies, Antiepileptic Drugs: Mechanisms of Action, 377-98, Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Raven Press, New York, 1980.

1799. DeLorenzo, R. J., Phenytoin: calcium- and calmodulin- dependent protein phosphorylation and neurotransmitter release, Antiepileptic Drugs: Mechanisms of Action, 399-414, Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Raven Press, New York, 1980.

1800. DeLorenzo, R. J. and Freedman, S. D., Phenytoin inhibition of neurotransmitter release and protein phosphorylation, Neurology, 28(4): 367-68, 1978.

1801. DesRosiers, M., Grave, G. D., Kupferberg, H. J. and Kennedy, C., Effects of diphenylhydantoin on local cerebral blood flow, Pharmacology and Anesthesia, 339-42, Springer-Verlag, New York, 1975.

1802. Deupree, J. D. and Weaver, J. A., Inhibition of rat brain phosphodiesterases and adenylate cyclase by phetiytoin, Fed. Proc. 38(3): 754, March, 1979.

1803. De Weer, P., Phenytoin: blockage of resting sodium channels, Antiepileptic Drugs: Mechanisms of Action, 353-61, Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Raven Press, New York, 1980.

1804. Dhatt, M. S., Akhtar, M., Reddy, C. P., Gomes, J. A. C., Lau, S. H., Caracta, A. R. and Damato, A. N., Modification and abolition of re-entry within the His-Purkinje system in man by diphenylhydantoin, Circulation, 56(5): 720-26, 1977.

1805. Dhatt, M. S., Gornes, J. A. C., Reddy, C. P., Akhtar, M., Caracta, A. R., Lau, S. H. and Damato, A. N., Effects of phenytoin on refractoriness and conduction in the human heart, J. Cardiovasc. Surg., 1: 3-18, 1979.

1806. Dilman, V. M. and Anisimov, V. N., Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice, Gerontology, 26: 241-6, 1980.

1807. Dilman, V. M., Bershtein, L. M., Tsyriina, E. V., Bobrov, Y. F., Kovaleva, I. G., Vasileva, I. A. and Kryloya, N. V., The correction of endocrinous metabolic disturbances in oncological patients. The effect of biguanides (phenformin and adebit), miskleron, and diphenine, Vopr. Onhol., 21(11): 33-9, 1975.

1808. Dodrill, C. B., Diphenylhydantoin serum levels, toxicity, and neuropsychological performance in patients with epilepsy, Epilepsia, 16: 593-600, 1975.

1809. Drazin, B., Ayalon, D., Hoerer, E., Oberman, Z., Harell, A., Ravid, R. and Laurian, L., Effect of diphenylhydantoin on patterns of insulin secretion in obese subjects, Acta Diabetol. Lat., 14: 51-61, Jan/Apr 1977.

1810. Dreifus, L. S. and Morganroth, J., Antiarrhythmic agents and their use in therapy, Pharmacol. Ther., 9: 75-106, 1980.

1811. Dretchen, K. L., Standaert, F. G. and Raines, A., Effects of phenytoin on the cyclic nucleotide system in the motor nerve terminal, Epilepsia, 18(3): 337-48, 1977.

1812. Duckrow, R. B. and Taub, A., The effect of diphenylhydantoin on self mutilation in rats produced by unilateral multiple dorsal rhizotomy, Epilepsy Abstracts, 11(l): 27,1977.

1813. Duperrat, B., Puissant, A., Saurat, J. H., Delanoe, J., Doyard, P. A. and Grunfels, J. P., Fabry’s disease neonatal angiokeratomas. Effect of diphenylhydantoin on acute pain episodes, Ann. Derm. Syph. (Paris), 102(4): 392-3, 1975.

1814. Eadie, M. J., The management of vertigo, Med. J. Aust., 135-6, July 26, 1975.

1815. Ehring, G. R. and Hondeghem, L. M., Rate, rhythm and voltage dependent effects of phenytoin: a test of a model of the mechanisms of action of antiarrhythmic drugs, Proc. West. Pharmacol. Soc., 21: 63-5, 1978.

1816. Ehrnebo, M. and Odar-Cederlof, I., Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraernic patients, Europ. J. Clin. Pharmacol., 8: 445-53, 1975.

1817. Eisenberg, M., Stevens, L. H. and Schofield, P. J., Epidermolysis bullosa-new therapeutic approaches, Aust. J. Derm., 19: 1-8, 1978.

1818. Elfstrom, J., Plasma protein binding of phenytoin after cholecystectomy and neurosurgical operations, Acta Neurol. Scand., 55: 455-64, 1977.

1819. Ellenberg, M., Unremitting painful diabetic neuropathy, JAMA, 237(18): 1986, 1977.

1820. Elliott, P. N. C., jenner, P., Chadwick, D., Reynolds, E. and Marsden, C. D., The effect of diphenylhydantoin on central catecholamine containing neuronal systems, J. Pharm. Pharmac., 29:41-3,1977.

1821. Ellis, J. M. and Lee, S. I., Acute prolonged confusion in later life as an ictal state, Epilepsia, 19: 119-28, 1978.

1822. El-Sherif, N. and Lazzara, R., Re-entrant ventricular arrhythmias in the late myocardial infarction period, 5. Mechanism of action of diphenylbydantoin, Circulation, 57(3): 465-73, 1979.

1823. Entrikin, R. K., Patterson, G. T., Weidoff, P. M. and Wilson, B. W., Righting ability and skeletal muscle properties of phenytoin-treated dystrophic chickens, Exp. Neural., 61: 650-63, 1978.

1824. Entrikin, R. K., Swanson, K. L., Weidoff, P. M., Patterson, G. T. and Wilson, B. W., Avian muscular dystrophy: functional and biochemical improvement with diphenythydantoin. Science, 195: 873-5, 1977.

1825. Esparza-Ahumada, S., Chapa-Alvarez, R., AndradePerez, J. S. and Rodriguez-Noriega, E., The improvement of chronic vascular leg ulcers while on treatment with diphenylhydantoin sodium, Personal Communication, 1981.

1826. Eviatar, L. and Eviatar, A., Vertigo in children: differential diagnosis and treatment, Pediatiics, 59: 833-8, 1977.

1827. Faugier-Grimaud, S., Action of anticonvulsants on pentylenetetrazol-inducecl epileptiform activity on invertebrate neurotics (Helix aspersa), Epilepsy Abstracts, 12(ii): 489, 1979.

1828. Ferrendelli, J. A., Phenytoin: cyclic nucleotide regulation in the brain, Antiepileptic Drugs: Mechanisms of Action, 429-33, Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Raven Press, New York, 1980.

1829. Ferrendelli, J. A. and Kinscherf, D. A., Inhibitory effects of anticonvulsant drugs on cyclic nucleotide accumulation in brain, Ann. Neurol., 5: 533-8, 1979.

1830. Ferrendelli, J. A. and Kinscherf, D. A., Phenytoin: effects on calcium flux and cyclic nucleotides, Epilepsia, 18(3): 331-6, 1977.

1831. Ferrendelli, J. A. and Kinscherf, D. A., Similar effects of phenytoin and tetrodotoxin on cyclic nucleotide regulation in depolarized brain tissue, J. Pharm. Exp. Ther., 207(3): 787-93, 1978.

1832. Fincham, R. W. and Schottelius, D. D., Decreased phe. nytoin levels in antineoplastic therapy, Ther. Drug Monitoring, 1: 277-83,1979.

1833. Finelli, P. F., Phenytoin and methadone tolerance, New Eng. J. Med., 294(4): 227, 1976.

1834. Fisher, J. D., Cohen, H. L., Mehra, R., Altschuler, H., Escher, D. J. W. and Furman, S., Cardiac pacing and pacemakers II. Serial electro-physiologic-pharrnacologic testing for control of recurrent tachyarrhythmias, Am. Heart J., 93(5): 658-68, 1977.

1835. Fleming, K., Japanese encephalitis in an Australian soldier returned from Vietnam, Med. J. Aust., 2: 19-23, 1975.

1836. Friis, M. L., Epilepsy among parents of children with facial clefts, Epilepsia, 20: 69-76, 1979.

1837. Fromm, G. H., Glass,j. D., Chattha, A. S. and Martinez, A. J., Effect of anticonvulsant drugs orr inhibitory and excitatory pathways, Epilepsia, 22: 65-73, 1981.

1838. Fromm, G. H., Glass, J. D., Chattha, A. S. and Terrence, C. F., Role of inhibitory mechanisms in trigeminal neuralgia, Neurology, 30: 417, 1980.

1839. Fry, B. and Ciarlone, A. E., Phenytoin increases norepinephrine (NE) and serotonin (5-HT) in mouse cerebellum, Pharmacologist, 21(3): 183, 1979.

1840. Frymoyer, J. W., Fracture healing in rats treated with diphenylhydantoin (Dilantin), J. Trauma, 16(5): 368-70, 1976.

1841. Fukuyama, Y., Ochiai, Y., Hayakawa, T. and Miyagawa, F., Overnight sleep EEG and cerebrospinal fluid monoamines in seizures induced by movement, Neuropadiatrie, 10(2): 138-49, 1979.

1842. Furman, R. E. and Barchi, R. L., The pathophysiology of myotonia produced by aromatic carboxylic acids, Ann. Neurol., 4(4): 357-65, 1978.

1843. Gage, P. W., Lonergan, M. and Torda, T. A., Presynaptic and postsynaptic depressant effects of phenytoin sodium at the neuromuscular junction, Br. J. Pharmac., 69: 119-21, 1980.

1844. Gage, P. W. and Spence, I., The origin of the muscle fasciculation caused by funnel-web spider venom, Epilepsy Abstracts, 11(9): 364, 1978.

1845. Gailaghan, J. T., Kinetic inhibition studies of microsomal phenytoin (DPH), Fed. Proc., 35(3): 408, 1976. 

1846. Gangji, D., Schwade, J. G. and Strong, J. M., Phenytoinmisonidazole: possible metabolic interaction, Cancer Treat. Rep., 64(i): 155-6, 1980.

1847. Garson, A., Kugler, J. D., Gillette, P. C., Simonelli, A. and McNamara, D. G., Control of late postoperative ventricular arrhythmias with phenytoin in young patients, Am. J. Cardiol., 46(2): 290-4, 1980.

1848. Gautray, J. P., jolivet, A., Goldenberg, F., Tajchner, G., and Eberhard, A., Clinical investigation of the menstrual cycle. II Neuroendocrine investigation and therapy of the inadequate luteal phase, Fertility and Sterility, 29(3): 275-281, 1978.

1849. Gelchrter, T. D., Enzyme induction (second of three parts), New Eng. J. Med., 294(11): 589-95, 1976.

1850. Gibberd, F. B. and Webley, M., Studies in man of phenytoin absorption and its implication, Epilepsy Abstracts, 9(2): 78, 1976.

1851. Gibbs, M. E. and Ng, K. T., Diphenylhydantoin facilitation of labile, protein-independent memory, Brain Research Bulletin, 1: 203-8, 1976.

1852, Gibbs, M. E. and Ng, K. T., Psychobiology of memory: towards a model of memory formation, Biobehaviorat Reviews, 1: 113-36,1977.

1853. Gilbert, J. C., Diseases of the cardiovascular systemdrugs affecting the cardiovascular system: pharmacological basis of treatment, Br. Med. J.., 31-3, 1976.

1854. Gilbert, J. C. and Wyllie, M. G., Effects of anticonvulsant and convulsant drugs on the ATPase activities of synaptosomes and their components, Br. J. Pharmac., 56: 49-57, 1976.

1855. Gilbert, J. C. and Wyllie, M. G., The relationship between nerve terminal adenosine triphosphatases and neurotransmitter release: as determined by the use of antidepressant and other CNS-active drugs, Br. J. Pharmae., 69: 215-25, 1980.

1856. Gill, M. A., Miscia, V. F. and Gourley, D. R., The treatment of common cardiac arthythmias, J. Amer. Pharm. Assn., NS16(t): 20-9, Jan. 1976.

1857. Gillette, P. C. and Garson, A., Electrophysiologic and pharmacologic characteristics of automatic ectopic atrial tachycardia, Circulation, 56: 571-5, 1977.

1858. Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Antiepileptic Drugs: Mechanisms of Action, Raven Press, New York, 1980.

1859. Goldberg, M. A., Phenytoin: binding, Antiepileptic Drugs: Mechanisms of Action, 323-37, Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Raven Press, New York, 1980.

1860. Goldberg, M. A., Phenytoin, phospholipids and calcium, Neurology, 27: 827-33, 1977.

1861. Goldberg, M. A. and Crandall, P. H., Human brain binding of phenytoin, Neurology, 28: 881-5, 1978.

1862. Goldberg, M. A. and Todoroff, T., Phenytoin binding to brain phospholipids, Neurology, 26: 386, 1976.

1863. Goldberg, M. A., Todoroff, T. and Crandall, P., Phenytoin binding to human brain, Neurology, 27(4): 374, 1977.

1864. Goldman, E., Aldrete, J. A. and Sherrill, D., Phenytoin brain protection in acute reversible hypoxia, 7th World Congress of Anaesthesiologists, Hamburg, 215-6, Sept. 1980.

1865. Goldsmith, S. and From, A. H. L., Arsenic-induced atypical ventricular tachycardia, New Eng. J. Med., 303(19): 1096-8, 1980.

1866. Goodenough, D. J., Fariello, R. G., Annis, B. L. and Chun, R. W. M., Familial and acquired paroxysmal dyskinesias, Arch. Neurol., 35: 827-31, 1978.

1867. Goultschin, J. and Shoshan, S., Inhibition of collagen breakdown by diphenylhydantoin, Biochim. Biophys. Acta, 631: 188-91, 1980.

1868. Grafova, V. N., Danilova, E. 1. and Kryzhanovskii, G. N., Analgesic effects of antiepileptic drugs in a pain syndrome of spinal origin, Bull. Exp. Biol. Med., 88(8): 837-40, 1979.

1869. Green, R. S. and Rau, J. H., The use of diphenylhydantoin in compulsive eating disorders; further studies, Anorexia Nemosa, 377-82, Vigersky, R. A., Ed., Raven Press, New York, 1977.

1870. Greenblatt, D. J., Allen, M. D., Koch-Weser, J. and Shader, R. I., Accidental poisoning with psychotropic drugs in children, Am. J. Dis. Child, 130: 507-11, 1976.

1871. Greenblatt, D. J. and Shader, R. I., Intravenous phenytoin, New Eng. J. Med., 1078, 1976.

1872. Griggs, R. C., Moxley, R. T., Riggs, J. E. and Engel, W. K., Effects of acetazolamide on myotonia, Ann. Neurol., 3: 531-7, 1978.

1873. Gustafson, A., Svensson, S. E. and Ugander, L., Cardiac arrhythmias in chloral hydrate poisoning, Acta Med. Scand., 201: 227-30, 1977.

1874. Hadfield, M. G. and Rigby, W. F. C., Dopamine: Adaptive uptake changes in striatal synaptosomes after 30 seconds of intense fighting, Biochem. Pharmacol., 25: 2752-4, 1976.

1875. Hadfield, M. G. and Weber, N. E., Effect of fighting and diphenylhydantoin on the uptake of 3H-1-norepinephrine in vitro in synaptosomes isolated from retired male breeding mice. Biochem. Pharmacol., 24: 1538-40, 1975.

1876. Haffner, Z. and Hovarth, E., Pseudomyotonia (Isaacssyndroma), Orvosi Hetilap, II 6(49): 2895-7, 1975.

1877. Hahn, T. J., Dibartelo, T. F. and Halstead, L. R., Comparative effects of diphenylhydantoin (DPH) and ouabain (0u) 45Ca release from cultured fetal rat forelimb rudiments, Clin. Res., 26(5): 681A, 1978.

1878. Hahn, T. J., Scharp, C. R., Richardson, C. A., Halstead, L. R., Kahn, A. J. and Teitelbaum, S. L., Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro, J. Clin. Invest., 62: 406-14,1978.

1879, Hamed, M. A., Abdel-Aal, H. M., Abdel-Aziz, T. M., Nassar, S. K., Sweify, S. M., Atta, S. M., El-Awady, S. M., El-Aref, M., El-Garf, A. R., A trial of diphenylhydantoin in periodic disease (familial Mediterranean fever) in Egyptian children, J. Egypt. Med. Assoc., 58(1/4): 205-15, 1975.

1880. Hamer, J., Diseases of the cardiovascular system-cardiac failure, Br. Med. J.., 220-4, 1976.

1881. Hansotia, P., Mazza, J. J. and Gatlin, P., Diphenylhydantoin and fragility of erythrocytes in normal subjects and in patients with hereditary spherocytic anemia. Amer. J. Clin. Path., 64(i): 75-9, 1975.

1882. Hanstom, L. and Jones, I. L., The effect of diphenylhydantoin upon degradation of sulphated macromolecules in cat palatal mucosa in vitro, Med. Biol., 57: 177-81, 1979.

1883. Hardie, R. A. and Savin, J. A., Drug-induced skin diseases, Br. Med. J.., 935-7, 1979.

1884. Haruda, F., Phenytoin hypersensitivity, Neurology, 29: 1480-5,1979.

1885. Harvey, S. C., The effects of ouabain and phenytoin on myocardial noradrenaline, Arch. Int. Pharmacodyn., 213(2): 222-34,1975.

1886. Hatangdi, V. S., Boas, R. A. and Richards, E. G., Post herpetic neuralgia: management with antiepileptic and tricyclic drugs, Advances in Pain Research and Therapy, Vol. 1, 583-587, Bonica, J. J. and Albe-Fessard, D., Eds., Raven Press, New York, 1976.

1887. Haward, L. R. C., Augmentation of autogenic training by sodium diphenylhydantoinate, World J. Psychosynthesis, 8: 2629,1976.

1888. Haward, L. R. C., Impairment of flying efficiency in anancastic pilots, Aviation, Space & Environmental Medicine, 156161,1977.

1889. Heesen, H. and Lahrtz, H., Treatment of severe digitalis intoxication in suicidal attempt, Med. Klin., 70: 812-6, 1975.

1890. Hegarty, B. A., Treatment of severe self-imposed overdose of phencyclidine hydrochloride, Bulletin Sinai Hosp., Detroit, 23(3): 147-51, 1975.

1891. Heinonen, 0. P., Slone, D. and Shapiro, S., Birth defects and drugs in pregnancy, Lancet (Review) 1086, 1977.

1892. Helfant, R. H., Effectiveness of diphenylhydantoin as an antihypertensive, Personal Communication, 1975.

1893. Henry, D. A., Bell, G. D. and Glithero, P., Plasma high-density lipoproteins, New Eng. J. Med., 300(14): 798, 1979.

1894. Herishanu, Y., Eylath, U. and Ilan, R., ‘In vitro’studies on the fate of diphenylhydantoin in uremia, Neurosci. Lett., 2: 97-101, 1976.

1895. Herishanu, Y., Eylath, U. and Ilan, R., Effects of calcium content of diet on absorption of diphenylhydantoin, Israel Med. Sci., 12(12): 1453-6, 1976.

1896. Hertz, L., Drug-induced alterations of ion distribution at the cellular level of the central nervous system, Pharmacol. Rev., 29(i): 35-65, 1977.

1897. Herzberg, G. R., Challberg, M. D., Hess, B. C. and Howland, J. L., Elevated potassium efflux from dystrophic diaphragm: influence of diphenylhydantoin and lithium, Biochem. Biophys. Res. Commun., 63(4): 858-63, 1975.

1898. Heyma, P., Larkins, R. G., Perry-Keene, D., Peter, C. T., Ross, D. and Sloman, J. G., Thyroid hormone levels and protein binding in patients on long-term diphenylhydantoin treatment, Clin. Endocrin, 6: 369-76, 1977.

1899. Homan, R. W., Vasko, M. R. and Blaw, M., Phenytoin plasma concentrations in paroxysmal kinesigenic choreoathetogis, Neurology, 30: 673-76, 1980.

1900. Hondeghem, L. M., Effects of lidocaine, phenytoin and quinidine on the ischemic canine myocardium, J. Electrocardiol., 9(3): 203-9, 1976.

1901. Hondeghem, L. M., Effects of quinidine, lidocaine and phenytoin on the excitability of the ischemic rabbit heart, Proc. West. Pharmacol. Soc., 19: 320-22, 1976.

1902. Hufnagl, H. D. and Sen, S., Phenytoin infusions in medical intensive care, Forischr. Med., 96: 415-24, 1978.

1903. Hulce, V. D., The action of chlorpromazine and phenytoin on muscle rigidity due to cerebellar lesions, Society for Neuroscience, III: 372, 7th Annual Meeting, Nov. 7-10, 1977.

1904. Ifabumuyi, O. I. and Jeffries, J. J., Treatment of drug-induced psychosis with diphenylhydantoin, Can. Psychiatr. Assoc. J., 21: 565-9, 1976.

1905. Ionasescu, V., Ionasescu, R., Witte, D., Feld, R., Cancilla, P., Kaeding, L., Kraus, L. and Stern, L., Altered protein synthesis and creatine kinase in breast muscle cell cultures from dystrophic chick embryos, J. Neurol. Sci., 46: 157-68, 1980.

1906. Ionasescu, V., Stern, L. Z., lonasescu, R. and Rubenstein, P., Stimulatory effects of drugs for protein synthesis on muscle cell cultures in Duchenne dystrophy, Ann. Neurol, 5: 107-10, 1979.

1907. Irani, P. F., Purohit, A. V., and Wadia, N. H., The syndrome of continuous muscle fiber activity, Acta Neurol. Scand., 55:273-88,1977.

1908. Ishibashi, F., Hamasaki, A., Shibata, Y., Naitoh, Y. and Kawate, R., Protection against alloxan inhibition of insulin release by glucose, cytochalasin B and diphenylhydantoin, Hiroshima. Med. Sci., 25(4): 199-202, 1976.

1909. Itil, T. M. and Seaman, P., Drug treatment of human aggression ., Prog. Neuro-Psychopharmacol., 2: 659-69, 1978.

1910. Jackson, D. L., Satya-Murti, S., Davis, L. and Drachman, D. B., Isaacs syndrome with laryngeal involvement: an unusual presentation of myokymia, Neurology, 29: 1612-5, 1979.

1911. JAMA, Questions and Answers, Recurrent transient motor aphasia in 39-year-old woman, JAMA, 238(23): 2541-2, 1977.

1912. JAMA, Questions and Answers, Anticonvulsant therapy and athletic performance, JAMA, 240(1): 59-60, 1978.

1913. Jannetta, P. J., Glossopharyngeal neuralgia, JAMA, 239(20): 2173, 1978.

1914. Jennett, W. B., An Introduction to Neurosurgety, 109, C. V. Mosby, St. Louis, 1970.

1915. Johanson, C. E. and Smith, Q. R., Phenytoin-induced stimulation of the Na-K pump in the choroid plexus cerebrospinal fluid system, Society for Neuroscience, III: 316, 7th Annual Meeting, Nov. 7-10, 1977.

1916. Johnson, R. N., Englander, R. N., Quint, S. R., Hanna, G. R., Control of excitability and threshold in the thalamocortical motor system of the cat by cerebellar stimulation, Epilepsy Abstracts, 9(9): 277, 1976.

1917. Johnston, D. and Ayala, G. F., Diphenylhydantoin: action of a common anticonvulsant on bursting pacemaker cells in aplysia, Science, 189: 1009-11, 1975.

1918. Jonas, A. D., When a subclinical psychomotor seizure posesasan,eurosis, Medical Builetin of the U.S. Army, Europe, 32(5): 174-76, 1975.

1919. Kamio, M. and Sugita, T., Syncopal attacks with loss of consciousness and abnormal EEG in childhood, Epilepsy Abstracts, 10(6): 180, 1977.

1920. Kannan, K., Dash, R. J. and Rastogi, G. K., Evaluation of treatment of painful diabetic neuropathy with diphenylhydantoin, J. Diabetic Assoc. India, 18; 199-202, 1978.

1921. Karmazyn, M., Horrobin, D. F., Morgan, R. O., Manku, M. S., Ally, A. I. and Karmali, R. A., Diphenylhydantoin: a prostaglandin antagonist in the rat mesenteric vasculature, IRCS Medical Science, 5: 332, 1977.

1922. Kerstein, M. D., and Firestone, L., The role of Dilantin (DPH) in the prevention of the pulmonary lesions associated with CNS hypoxia, Clin. Res., 25(3): 419A, April, 1977.

1923. Keith, D. A., Side effects of diphenylhydantoin: a review, J. Oral Surg., 36: 206-10, 1978.

1924. Kinscherf, D. A. and Ferrendelli, J. A., Tetrodotoxinlike effect of phenytoin on cyclic nucleotide regulation in brain, Fed. Proc., 37(3): 341, 1978.

1925. Kloppel, G., Functional pathomorphology of the pancreatic P cell system-Ultrastructural and calcium-cytochemical studies on insulin biosynthesis and secretion, Veroeff Pathol., 108: 54-8, 1977.

1926. Koch, M. M., Lorenzini, I., Freddara, U., Jezequel, A. M. and Orlandi, F., Type 2 Crigler-Najjar syndrome. Quantitation of ultrastructural data and evolution under therapy with phenytoin, Gastroenterol. Clin. Biol., 2: 831-42, 1978.

1927. Koch-Weser, J., The serum level approach to individualization of drug dosage, Europ. J. Clin. Pharmacol., 9: 1-8, 1975.

1928. Koch-Weser, J. and Sellers, E. M., Binding of drugs to serum albumin (First of two parts), New Eng. J. Med., 294(6): 311-9,1976.

1929. Koch-Weser, J. and Sellers, E. M., Binding of drugs to serum albumin (Second of two parts), New Eng. J. Med., 294(10): 526-31, 1976.

1930. Komatsu, K. and Sato, M., A comparison between ouabain treated and genetically dystrophic mice with reference to the effect of phenytoin on the membrane potential of their skeletal muscles, Yakugaku Zasshi, 99(8): 855-8, 1979.

1931. Kontani, H., Kudo, Y. and Fukuda, H., Effect of drugs affecting sodium permeability on the muscle spindle of the frog, Folia Pharmacol. Japan, 72: 325-30, 1976.

1932. Korczyn, A. D., Shavit, S. and Schlosberg, I., The chick as a model for malignant hyperpyrexia, Europ. J. Pharmacol., 61: 187-9, 1980.

1933. Komblith, P. L., Hartnett, L. C., Anderson, L. P., Quindien, E. A., and Smith, B. H., Growth-inhibitory effect of diphenylhydantoin on murine astrocytomas, Neurosurgery, 5(2): 259-63, 1979.

1934. Kornblith, P. L., Callahan, L. V. and Caswell, P. A., Growth-inhibitory effects of diphenylhydantoin on human brain tumor cells in culture, Neurosurgery, 2(2): 122-7, 1978.

1935. Kornblith, P. L., Caswell, P. A., Bogoch, S., Callahan, L. V. and Dreyfus, J., Effects of diphenylhydantoin on cultured human glial cells, In Vitro, 324, April, 1976.

1936. Kramer, M. S., Menstrual epileptoid psychosis in an adolescent girl, Amer. J. Dis. Child., 131: 316-7, 1977.

1937. Krumdieck, C. L., Fukushima, K., Fukushima, T., Shiota, T. and Butterworth, C. E., A long-term study of the excretion of folate and pterins in a human subject after ingestion of 14C folic acid, with observations on the effect of diphenylhydantoin administration, Am. J. Clin. Nuir., 31: 88-93, 1978.

1938, Kupferberg, H. J., Lust, W. D., Yonekawa, W., Passonneau, J. V. and Penry, J. K., Effect of phenytoin (Diphenylbydantoin) on electrically-induced changes in the brain levels of cyclic nucleotides and GABA, Fed. Proc., 35: 583, March, 1976.

1939. Kurihara, T., Tawara, S., Araki, S., Okamoto, S. and Shirabe, T., The therapeutic effects of diphenylhydantoin for myotonia and electron microscopic studies of Thomsen’s disease, Clin. Neurol. (Tokyo), 16: 661-8, 1976.

1940. Kutt, H. and Solomon, G. E., Phenytoin: relevant side effects, Antiepileptic Drugs: Mechanisms of Action, 435-45, Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Raven Press, New York, 1980.

1941. Laia, V. R., J uan, C. S., and AvRuskin, T. W., Effect of diphenylhydantoin (DPH) on arginine-induced glucagon (IRC) secretion in juvenile diabetes mellitus (I DM), Pediatr. Res., II: 5 1 7, April 1977.

1942. LaManna, J., Lothman, E., Rosenthal, M., Somjen, G. and Younts, W., Phenytoin, electric, ionic and metabolic responses in cortex and spinal cord, Epikpsia, 18(3): 317-29, 1977.

1943. Lance, J. W., Burke, D. and Pollard, J., Hyperexcitability of motor and sensory neurons in neuromyotonia, Ann. Neurol., 5: 523-32, 1979.

1944. Lancet, Editor, Liquid-protein diets and ventricular tachycardia, Lancet, 976, 1978.

1945. Lancet, Editor, Tinnitus, Lancet, 1124, 1979.

1946. Lappas, D. G., Powell, W. M. J. and Daggett, W. M., Cardiac dysfunction in the perioperative period, Anesthesiology, 47: 117-37, 1977.

1947. Laxer, K. D., Robertson, L. T., Julien, R. M. and Dow, R. S., Phenytoin: relationship between cerebellar function and epileptic discharges, Antiepileptic Drugs: Mechanisms of Action, 415-27, Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Raven Press, New York, 1980.

1948. Lechin, F. and van der Dijs, B., Effects of diphenylhydantoin (DPH) on distal colon motility, Acta Gastroenterol. Latinoam, 9(3): 145-52, 1979.

1949. Lee, Y. T., Lee, T. K. and Tsai, H. C., Glossopharyngeal neuralgia as the cause of cardiac syncope, J.Formosan Med. Assoc., 74: 103-7, 1975.

1950. Leon-Sotomayor, L., A new technique in the treatment of thromboembolic stroke, Angiology, 31(11 729-43, 1980.

1951. Levin, S. R., Charles, M. A., O’Connor, M., Grodsky, G. M., Use of diphenylhydantoin and diazoxide to investigate insulin smretory mechanisms, Amer J. Physiol., 229(l): 49-54, July, 1975.

1952. Levin, S. R., Driessen, J. and Kasson, B., Adenosinetriphosphatases of pancreatic islets: comparison with those of kidney, Endocr. Soc. Program, 59: 75 (Abstract 38), 1977.

1953. Levin, S. R., Kasson, B. G. and Driessen, J. F., Adenosine triphosphatases of rat pancreatic islets-comparison with those of rat kidney, J. Clin. Invest., 62: 692-70’1, 1978.

1954. Levinson, S., Canalis, R. F. and Kaplan, H. J., Laryngeal spasm complicating pseudomyotonia, Arch. Otolaryngol., 102: 185-7, 1976.

1955. Levo, Y., Markowitz, 0. and Trainin, N., Hydantoin immunosuppression and carcinogenesis, Clin. Exp. Immun., 19: 521-7, March 1975.

1956. Levy, R. H., Phenytoin: biopharmacology, Antiepileptic Drugs: Mechanisms of Action, 315-2 1, Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Raven Press, New York, 1980.

1957. Lewin, E., Effects of phenytoin on the release of 14C-Adenine derivatives, Epilepsia, 18(3): 349-55, 1977.

1958. Lewin, E. and Bleck, V., Cyclic AMP accumulation in cerebral cortical slices: effect of carbamazepine, phenobarbital and phenytoin, Epilepsia, 18(2): 237-42, 1977.

1959. Lewis, D. V., Zbiez, K. 1. and Wilson, W. A., Diphenylhydantoin depresses firing in the aplysia giant neuron by blocking a slow inward current, Soc. for Neuroscience, 251, 9th Annual Meeting, Nov. 2-6,1979.

1960. Lewis, J. S., Gilbert, B. and Garry, P. J., Glutathione reductase activity coefficients of children on anticonvulsant drugs and their normal siblings, Fed. Proc., 37 (Abstract 2412): 671, March 1978.

1961. Linden, V., Brevik, J. I., and Hansen, T., Phenytoin, phenobarbitone and serum cholesterol, Scand. J. Soc. Med., 5: 123-5, 1977.

1962. Livingston, S., Phenytoin and serum cholesterol, Epilepsy Abstracts, 9(10): 329, 1976.

1963. Loeser, J. D., The management of tic douloureux, Pain, 3: 155-62, 1977.

1964. Loeser, J. D., What to do about tic douloureux, JAMA, 239(12): 1153-5, 1978.

1965. Loh, C. K., Katz, A. M. and Pierce, E. C., Interactions of diphenylhydantoin and cardiac glycosides on atrial potassium, Am. J. Physiol., 230(4): 965-69, 1976.

1966. Lown, B., Temte, J. V., Reich, P., Gaughan, C., Regestein, Q. and Hai, fi., Basis for recurring ventricular fibrillation in the absence of coronary heart disease and its management, New Eng. J. Med., 294(12): 623-29, 1976.

1967. Lublin, F. D., Tsairis, P., Streletz, L. J., Chambers, R. A., Riker, W. F., Van Poznak, A. and Duckett, S. W., Myokyrnia and impaired muscular relaxation with continuous motor unit activity, J. Neurol. Neurosurg. Psychiatry, 42: 557-62, 1979.

1968. Luoma, P. V., Myllyla, V. V., Sotaniemi, E. A. and Hokkanen, T. E. J., Plasma HDL cholesterol in epileptics with elevated triglyceride and cholesterol, Acta Neurol. Scand., 60: 56-63, 1979.

1969. Lust, W. D., Kupferberg, H. J., Yonekawa, W. D., Penry, J. K., Passonneau, J. V. and Wheaton, A. B., Changes in brain metabolites induced by convulsants or electroshock: Effects of anticonvulsant agents, Molec. Pharmacol., 14: 347-56, 1978.

1970. Lutschg, J., Jerusalem, F., Ludin, H. P., Vasselia, F. and Mumenthaler, M., The syndrome of ‘continuous muscle fiber activity, Arch. Neurol., 35: 198-205, 1978.

1971. Maisov, N. I., Tolmacheva, N. S. and Raevsky, K. S., Liberation of ‘H-gamma-aminobutyric acid (3H-GABA) from isolated nerve endings of the rat’s brain under the effect of psychotropic substances, Farmakol. Toksik., 39: 517-20, 1976.

1972. Mathews, E. C., Blount, A. W. and Townsend, Q-T prolongation and ventricular arrhythmias, with and without deafness, in the same family, Am. J. Cardiol., 29:702-11, 1972.

1973. Matthews, E. K. and Sakamoto, Y., Pancreatic islet cells: electrogenic and electrodiffusional control of membrane potential, J. Physiol., 246: 439-57, 1975.

1974. Matthews, W. D. and Connor, J. D., Actions of iontophoretic phenytoin and medazepam on hippocampal neurons, J. Pharmacol. Exp. Ther., 201(3): 613-21, 1977.

1975. Matthews, W. D. and Connor, J. D., Effects of diphenylhydantoin and diazepam on hippocampal evoked responses, Neuropharmacol., 15: 181-6, 1976.

1976. Medical Letter on Drugs and Therapeutics, Treatment of cardiac arrhythmias, 20(26): 113-20, 1978.

1977. Medical World News, Editor, New clues to averting liquid-protein deaths, Medical World News, 61, 1978.

1978. Melacini, P., Furlanut, M., Ferrari, M. and Volta, S. D., Effects of quinidine and diphenylhydantoin on membrane resistance in smooth muscle, Arch. Int. Pharmacodyn., 213(1): 17-21, 1975.

1979. Melding, P. S. and Goodey, R. J., The treatment of tinnitug with oral anticonvulsants, J. Laryng., 93: 111-22, 1979.

1980. Melikian, A. P., Straughn, A. B., Slywka, G. W. A., Whyatt, P. L. and Meyer, M. C., Bioavailability of I I phenytoin products, J. Pharmacokinet. Biopharm., 5(2): 133-46, 1977.

1981. Mentzer, R. M., Alegre, C. and Nolan, S. P., Effects of diphenyihydantoin (Dilantin) on the pulmonary circulation, Surgical forum, 26: 217-9, 1975.

1982. Merck Manual of Diagnosis and Therapy, 13th Edition, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey, 1977.

1983. Mesulam, M. M., Dissociative states with abnormal tem poral lobe EEG-multiple personality and the illusion of posses sion, Arch. Neurol., 38: 176-81, 1981.

1984. Migdal, S. D., Slick, G. L. and McDonald, F. D., Diphenylhydantoin (DPH) renal vasodilator, Clin. Res., 25(3): 273A, 1977.

1985. Migdal, S. D., Slick, G. L., Abu-Hamdan, D. and McDonald, F. D., Phenytoin, renal function and renin release, J. Pharmacol. Exp. Ther., 215(2): 304-8, 1980.

1986. Migdal, S. D., Slick, G. L. and McDonald, F. D., Phenytoin (DPH) renal function and renin secretion (RSR), Clin. Res., 26(3): 471, 1978.

1987. Millichap, J. G., Recurrent headaches in 100 children, Child’s Brain, 4: 95-105, 1978.

1988. Mohan, K. J., Salo, M. W. and Nagaswami, S., A case of limbic system dysfunction with hypersexuality and fugue state, Dis. Nerv. Syst., 36: 621-4, 1975.

1989. Moore, S. J., Digitalis toxicity and treatment with phenytoin: neurologic mechanism of action, Heart & Lung, 6(6): 1035-40,1977.

1990. Morgan, P. H. and Mathison, 1. W., Arrhythmias and antiarrhythmic drugs: mechanism of action and structure-activity relations, J. Pharm. Sci., 65: 467-81, 1976.

1991. Moss, G., The role of the central nervous system in shock: the centroneurogenic etiology of the respiratory distress syndrome, Critical Care Medicine, 2(4): 181-5, 1974.

1992. Muller, D. and Leuschner, U., Clinical and neurophysiological findings in blood-level controlled diphenylhydantoin application-considerations on the therapy of myotonic dystrophy, Psychiatr. Neurol. Med. Psychol., 32(8): 464-8, 1980.

1993. Muller, N. R., Tsyrlina, E. V., Ostroumova, M. N. and Shemerovskaya, T. G., The effect of diphenine on the growth and metastasis of experimental malignant tumors, Vopr. Onkol., 21(7): 86-90, 1975.

1994. Neldner, H. K., Treatment of localized linear scleroderma with phenytoin, Cutis, 22: 569-72, 1978.

1995. Nelson, E. W., Cerda, J. J., Wilder, B. J. and Streiff, R. R., Effect of diphenylhydantoin on the bioavailability of citris folate, Am. J. Clin. Nutr.., 31: 82-7, 1978.

1996. Neuman, R. S. and Frank, G. B., Effects of diphenyl hydantoin and phenobarbital on voltage-clamped myelinated nerve, Can. J. Physiol. Pharmacol., 55(1): 42-8, 1977.

1997. Neuvonen, P. J., Penttila, O., Lehtovaara, R. and Aho, K., Effect of antiepileptic drugs on the elimination of various tetracycline derivatives, Europ. J. Clin. Pharmacol., 9: 147-54, 1975.

1998. Nevsimal, O., Suta, M. and Tuhacek, M., The stiffman syndrome, Cesk. Neurol., 30(2): 133-8, 1967.

1999. Newell, 1. M., Trigeminal neuralgia: induced remission without surgery, and observations on its aetiology, Med. J. Aust., 1: 605-7, 1976.

2000. Newsom, J. A., Withdrawal seizures in an in-patient al coholism program, Currents in Alcoholism, vol. 6,11-14, Galanter, M., Ed., Grune and Stratton, New York, 1979.

2001. Nies, A. S., Cardiovascular disorders, 1. Alteration of arterial pressure and regional blood flow, Clinical Pharmacology, Basic Principles in Therapeutics, K. L. Meirnon and H. F. Morrelli, Eds., Macmillan, New York, 1972.

2002. Nikkila, E. A., Kaste, M., Ehnholm, C. and Viikari, J., Elevation of high-density lipoprotein in epileptic patients treated with phenytoin, Acta Med. Scand, 204: 517-20, 1978.

2003. Nishida, T., The effects of diphenylhydantoin sodium on the in vivo electroretinogram of rabbits, Epilepsy Abstracts, 9(2): 47,1976.

2004. Nishikaze, O., Furuya, E. and Takase, T., Diphenylhydantoin inhibits the production of lipid peroxide in carrageenin induced inflammation in rats, IRCS Med. Sci., 8: 552, 1980.

2005. Ochiai, Y., Hayakawa, T., Fukuyama, Y. and Miragawa, F., Analysis of overnight sleep EEG and cerebrospinal fluid monoamine metabolites in seizures induced by movement, Epilepsy Abstracts, 11(8): 297, 1978.

2006. O’Donnell, J. M., Kovacs, T. and Szabo, B., Influence of the membrane stabilizer diphenylhydantoin on potassium and sodium movements in skeletal muscle, Pflugers Arch, 358: 275-88, 1975.

2007. Oettinger, L., Interaction of methylphenidate and diphenylhydantoin, Drug Therapy, 5: 107-8, 1975.

2008. Opie, L. H., Drugs and the heart-IV antiarrhythmic agents, Lancet, 861-8, 1980.

2009. Otto, G., Ludewig, R. and Kotzschke, H. J., Specific action of local phenytoin application on periodontal disease, Stomatol. DDR, 27: 262-8, 1977.

2010. Ozawa, H., Komatsu, K. and Sato, M., Reversal by phenytoin (diphenylhydantoin) of the resting membrane potential of skeletal muscle from genetically dystrophic mice, J. Pharm. Soc. Japan, 98(3): 386-9, 1978.

2011. Pace, C. S. and Livingston, E., Ionic basis of phenytoin sodium inhibition of insulin secretion in pancreatic islets, Diabetes, 28: 1077-82, 1979.

2012. Palmer, G. C., Jones, D. J., Medina, M. A., Palmer, S. J. and Stavinoha, W. B., Anticonvulsants: action on central aden ylate cyclase systems, Pharmacoloot, 20: 231, 1978.

2013. Palmer, G. C., ]ones, D. J., Medina, M. A. and Stavinoha, W. B., Anticonvulsant drug actions on in vitro and in vivo levels of cyclic AMP in the mouse brain, Epilepsia, 20: 95-104, 1979.

2014. Pedley, T. A. and Guilleminault, C., Episodic nocturnal wanderings responsive to anticonvulsant drug therapy, Ann. Neurol., 2(l): 30-5, 1977.

2015. Pelkonen, R., Fogelholm, R. and Nikkila, E. A., Increase in serum cholesterol during phenytoin treatment, Br. Med. J.., 85, 1975.

2016. Pendefunda, G., Oprisan, C., Ciobanu, M. and Cozma, V., Clinico-electromyographic considerations on a case of neuro myotonia, Rev. Roum. Med. (Neurot. Psychiatr.), 13(4): 237-45, 1975.

2017. Pento, J. T., Diphenylhydantoin inhibitions of penta gastrin-stimulated calcitonin secretion in the pig, Horm. Metab. Res., 8: 399-401, 1976.

2018. Peppercorn, M. A., Herzog, A. G., Dichter, M. A. and Mayman, C. I., Abdominal epilepsy-a cause of abdominal pain in adults, JAMA, 240(22): 2450-51, 1978.

2019. Peraino, C., Fry, R. J. M., Staffeldt, E. and Christopher, P., Comparative enhancing effects of phenobarbital, amobarbital, diphenylhydantoin, and dichlorodiphenyltrichloroethane on 2-acetylaminofluorene-induced hepatic tumorigenesis in the rat, Cancer Res., 35: 2884-90, Oct. 1975.

2020. Perucca, E. and Richens, A., Water intoxication produced by carbamazepine and its reversal by phenytoin, Br. J. Clin. Pharmacol., 9: 302-4P, 1980.

2021. Perry, J. G., McKinney, L. and DeWeer, P., The cellular mode of action of the anti-epileptic drug 5, 5-diphenylhydantoin. Nature, 272: 271-3, 1978.

2022. Petrack, B., Czernik, A. J., Itterly, W., Ansell, J. and Chertock, H., On the suppression of insulin and glucagon released by diphenylhydantoin, Diabetes, 25, Suppl. 1: 380, 1976.

2023. Pincus, J. H., Yaari, Y. and Argov, Z., Phenytoin: electrophysiological effects at the neuromuscular junction, Antiepileptic Drugs: Mechanism of Action, 363-76, Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Raven Press, New York, 1980.

2024. Pollen, D. A., Responses of single neurons to electrical stimulation of the surface of the visual cortex, Brain Behav. Evol., 14: 67-86, 1977.

2025. Porras, C., Barboza, J. J., Fuenzalida, E., Adaros, H. L., de Diaz, A. M. 0. and Furst, J., Recovery from rabies in man, Ann. lnt. Med., 85: 44-48, 1976.

Advisory